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Abstract 
 
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), infects one third of the 
world’s population and kills 1.7 million people per year. The increasing prevalence of multi- and 
extensively drug resistant M. tuberculosis strains means that there is an urgent need to develop new 
anti-TB drugs. The genome of M. tuberculosis has five copies of the ESAT-6 gene clusters (ESX-1, 
-2, -3, -4 and -5), which are essential for the survival (ESX-3) and pathogenicity (ESX-1 and ESX-5) 
of the bacterium. The ESX clusters encode for proteins which form a novel secretion system which 
has been shown to secreted small T-cell antigens of the esx gene family, as well as other proteins 
such as the PE and PPE’s.  The mycosins are a family of genes situated in the ESX clusters which 
encode for putative subtilisin-like serine proteases.  These proteins are the most conserved proteins 
within the five clusters.  Apart from their conserved protein sequence, mycosin-3 is also an essential 
protein specific to the mycobacteria, which makes it an attractive potential drug target. Identifying 
the substrate(s) of mycosin-3 could help to understand the function of this enzyme and discover 
novel inhibitors from which new drugs could be designed. We hypothesize that the secreted 
products of the ESX system could be potential substrates for the mycosins.  Specifically, we 
hypothesize that PE5, PPE4, esxG and esxH (all found in ESX-3) might be the substrates for 
mycosin-3. Mycosin-3, PE5, PPE4, esxG and esxH were thus cloned, expressed and purified 
respectively. The four substrates were used for protease assays using mycosin-3 as the protease.  
The protease-substrate mixture were subsequently separated on 2-D SDS-PAGE gels to check 
whether there were any cleavage of the four substrates. Although all the target fusion proteins were 
cloned and expressed successfully, the protease assay results showed no cleavage for any of the four 
substrates. Possible explanations for the failure of cleavage were: (1) impure enzyme and 
substrate(s); (2) inappropriate buffer conditions; (3) the hypothesized substrates might not be the 
substrates of mycosin-3; and (4) incorrect folding or modification of the target fusion proteins might 
have taken place. Future research will aim to address these possible limitations in order to fully 
elucidate the function and substrate specificity of mycosin-3 and to use this information for the 
design of novel drugs against M. tuberculosis.   
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Opsomming 
 
Mycobacterium tuberculosis, die organisme wat tuberkulose (TB) veroorsaak, infekteer `n derde 
van die wêreld se bevolking en veroorsaak die dood van 1.7 miljoen mense per jaar.  Die verhoogde 
voorkoms van multi- en ekstensiewe middelweerstandige stamme van M. tuberculosis beteken dat 
daar `n ernstige nodigheid is om nuwe anti-TB middels te ontwikkel.  Die genoom van M. 
tuberculosis het vyf kopieë van die ESAT-6 geengroepe (ESX-1, -2, -3, -4 en -5), wat essensieel is 
vir die oorlewing (ESX-3) en patogenisiteit (ESX-1 and ESX-5) van die bakterium. Die ESX 
groepe enkodeer vir proteïene wat `n nuwe uitskeidingssisteem vorm wat bewys is om klein T-sel 
antigene van die esx geenfamilie, sowel as ander proteïene soos die PE en PPE proteïene uit te skei.  
Die mycosins is `n familie gene wat in die ESX geengroepe voorkom en wat waarskynlik enkodeer 
vir subtilisin-agtige serine proteases.  Hierdie proteïene is die mees gekonserveerde proteïene in die 
vyf geengroepe.  Mycosin-3 is `n essensiële protein wat spesifiek in die mikobakteriëe voorkom, 
sodat dit `n aantreklike teiken vir die ontwikkeling van middels is. Die identifisering van die 
substrate van mycosin-3 kan moontlik help om die funksie van die ensiem te verstaan en om nuwe 
inhibeerders vir die ensiem te ontdek, wat kan lei tot die onwikkeling van nuwe middels. Ons 
hipotese is dat die uitgeskeide proteïene van die ESX sisteem moontlik die substrate van die 
mycosin proteïene kan wees.  Meer spesifiek, ons hipnotiseer dat die proteïene PE5, PPE4, esxG en 
esxH (wat almal in ESX-3 voorkom) die substrate vir mycosin-3 kan wees. Mycosin-3, PE5, PPE4, 
esxG en esxH is afsonderlik gekloneer, uitgedruk en gesuiwer. Die vier substrate is gebruik vir 
protease proewe met mycosin-3 as die protease.  Die protease-substraat mengsel is hierna deur 
middel van 2-D SDS-PAGE geanaliseer om te kyk of daar enige kliewing van die vier substrate 
voorgekom het. Alhoewel al die teiken fusieproteïene suksesvol gekloneer, uitgedruk en gesuiwer is, 
het die protease proewe geen kliewing getoon vir enige van die vier potensiële substrate nie.  
Moontlike verklarings vir hierdie negatiewe resultaat is die volgende: (1) ensiem en substrate was 
moontlik onsuiwer; (2) bufferkondisies was moontlik nie korrek nie; (3) gehipotiseerde substrate 
mag moontlik nie substrate van mycosin-3 wees nie; en (4) nie-korrekte vouing of modifisering van 
die teiken proteïene kon moontlik plaasgevind het. Toekomstige navorsing sal daarop gemik wees 
om hierdie beperkinge aan te spreek om sodoende die funksie en substrate van mycosin-3 te kan 
ontdek en nuwe middels teen M. tuberculosis te ontwerp.   
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Chapter 1 Literature Review  
 
1.1 Status of Tuberculosis in the world 
Tuberculosis (TB) is a contagious pulmonary disease, the causative agent of which is 
Mycobacterium tuberculosis, a member of the high G+C gram-positive bacteria (Grange, 
2009). The organism is air-borne, thus the infection results from inhaling air containing 
bacteria mostly originating from coughing TB patients. M. tuberculosis is a very successful 
human pathogen carrying out sophisticated defense mechanisms, such as inhibiting 
acidification and maturation of the phagosome, and persisting inside human macrophages 
(Grange, 2009). Additionally, M. tuberculosis is well adapted to harsh environments 
(including limited nutrient supplies). M. tuberculosis infects one third of the world’s 
population (Global Tuberculosis Control, WHO, 2009). Infected persons may get diseased 
when their immune systems get compromised. Not surprisingly, there is a strong correlation 
between TB and HIV infection. TB causes more deaths than any other single infectious agent 
in human history (Grange, 2009). It has become a global health threat. According to World 
Health Organization (WHO) statistics, there were about 9.4 million incident cases of TB 
globally in 2008, and an estimated 1.3 million people died from TB in the same year. The 
highest number of deaths was in the South-East Asia Region, while the highest mortality per 
capita was in the Africa Region (Global Tuberculosis Control, WHO, 2009). Such a 
phenomenon indicates that TB has a high morbidity and mortality rate in populated and 
under-developed regions of the world. 
 
 
1.2 Emergence of drug-resistant tuberculosis 
M. tuberculosis evolved from non-tuberculous mycobacteria (NTM) which are mostly 
environmental mycobacteria (den Dooren de Jong, 1939). Dutch microbiologist den Dooren 
de Jong described tubercle bacillus as “the wayward son of honourable parents” in 1939. 
How M. tuberculosis evolved to become a human pathogen is still a mystery. Research on the 
interactions between environmental mycobacteria and protozoa provided some evidence. 
Primm and coworkers proposed that some environmental mycobacteria, including members 
of the M. avium complex, are able to replicate within various protozoans and also to survive 
within amoebic cysts under conditions of environmental stress (Primm et al., 2004). Such an 
intracellular replication may play an essential role in the evolution of mycobacteria to 
become intracellular pathogens. 
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Humans have been combating TB for centuries, although the causative agent was only 
discovered in 1882. The standard therapy for TB involves treatment with antibiotics, namely 
isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and ethambutol (EMB) for two 
months, then INH and RIF alone for another four months. The patient is considered as being 
cured after this regimen. These four drugs used for drug-sensitive M. tuberculosis strains are 
grouped as first line drugs because of their effectiveness and primary use. Unfortunately, 
drug-resistant TB emerged over the years due to poorly managed TB care, incorrect drug 
prescribing practices by providers, poor quality drugs, erratic supply of drugs, and also 
patient non-adherence (WHO, 2006). M. tuberculosis gradually adapted to the toxic effect of 
these drugs and become resistant through mutations of the genes encoding drug targets 
(shown in Table 1.1). 
 
Table 1.1 Targets of anti-mycobacterial agents and associated genetic loci (Grange, 2009) 
Agent Target molecule or 
function 
Genes and regions encoding for 
resistance 
Isoniazid Mycolic acid synthesis katG, inhA and its promoter 
region. oxyR-ahpC intergenic 
region 
Rifampicin DNA-dependent RNA 
polymerase 
rpoB 
Pyrazinamide Cell membrane energy 
function 
pncA 
Ethambutol Arabinogalactan 
synthesis 
embA, embB, embC 
Streptomycin Ribosomal protein S12 rpsL 
Ethionamide and 
prothionamide 
Mycolic acid synthesis ethA, inhA and its promoter 
region 
Capreomycin, Kanamycin, 
Amikacin and Viomycin 
50S and 30S ribosomal 
subunit 
vicA (50S), vicB (30S), rrs (16S) 
Cycloserine Peptidoglycan synthesis alrA 
Clofazimine ? RNA polymerase Unknown 
p-aminosalicyclic acid Folic acid synthesis Unknown 
Dapsone Folic acid synthesis Unknown 
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Multi-drug resistant (MDR) M. tuberculosis strains have recently emerged as a new threat 
which makes this global burden even worse. MDR-TB is caused by strains of M. tuberculosis 
that are resistant to at least the two main first-line TB drugs, namely INH and RIF. Epidemics 
of drug-resistant disease can be generated by three interrelated mechanisms: (1) conversion to 
drug-resistant strains from wildtype pan-susceptible strains during treatment (acquired 
resistance); (2) increasing development of resistance in drug-resistant strains due to 
inappropriate chemotherapy (amplified resistance); and (3) transmission of drug-resistance 
cases (transmitted resistance) (Blower et al., 2004). This process is still ongoing and 
extensive drug resistant (XDR) TB [defined as MDR-TB that is also resistant to any 
fluoroquinolone, and to at least one of three injectable second line anti-TB drugs used in TB 
treatment (capreomycin, kanamycin and amikacin)] has now emerged. 
 
 
1.3 Discovery of new anti-TB drugs 
Scientists have realized the urgency of efficiently combating TB and have thus been either 
designing derivatives of old drugs (making them more effective against drug-resistant TB) or 
looking for new alternative drug targets. Many new drugs have been discovered in the last 
few years, such as SQ109, PA-824, OPC-67683 and TMC207. 
 
SQ109 is a diamine analogue of ethambutol, which shows excellent in vitro activity against 
M. tuberculosis, including strains resistant to EMB, INH and RIF (Protopopova et al., 2005). 
This drug has a long half-life suggesting that once-a-week dosing is achievable. SQ109 is 
believed to target cell wall synthesis but with a different mechanism from EMB, perhaps a 
different target. The combination of SQ109 and RIF against TB is so potent that 99% of the 
growth was inhibited at very low concentrations (Chen et al., 2006). 
 
PA-824 is a lead compound of bicyclic nitroimidazo[2,1-b]oxazines, which was found to be 
active against M. tuberculosis without any unfavourable mutagenic features. PA-824 is able 
to inhibit M. tuberculosis cell wall lipid and protein synthesis (Stover et al., 2000). However, 
substitution of RIF or PZA with PA-824 appeared to deactivate the drug and a high relapse 
rate was observed after six months of a RIF, INH and PA-824 regimen. The sterilizing ability 
of the drug was limited (Nuermberger et al., 2006). 
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The drug, OPC-67683, which belongs to the 6-nitro-2,3-dihydroimidazo[2,1-b]oxazole series, 
targets mycolic acid. It inhibits mythoxy-mycolic and keto-mycolic acid synthesis, but not α-
mycolic acid synthesis, at significantly lower concentration than INH. A combined treatment 
of OPC-67683 with RIF and PZA for a 2 months followed by a combination with RIF for 
another 2 months eliminates all lung bacteria within 3 months. It suggests that this drug has a 
powerful sterilizing ability and may be effective in shorter treatments (Matsumoto et al., 
2006). 
 
TMC207 is the most potent molecule among the series of diarylquinolines (DARQs). It 
exhibits excellent activity against drug-susceptible, MDR and XDR M. tuberculosis strains, 
with no cross-resistance to first-line drugs (Andries et al., 2005). TMC207 acts by inhibiting 
mycobacterium membrane-bound ATP synthase. This mechanism has little similarity with 
mycobacterial and human proteins encoded by the atpE gene that codes for the c subunit of 
ATP synthase, so it has great potential (Andries et al., 2005). Combination of TMC207 with 
first-line drugs results in elimination of the bacteria in mouse models within two months. 
 
More recently, a group of 36 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives 
have been developed for screening as anti-TB agents (Ancizu et al., 2010). This stemmed 
from the efficacy of quinoxaline and quinoxaline 1,4-di-N-oxide derivatives displaying 
excellent anti-parasitic, anticancer, antiviral, and antibacterial activities in many different 
therapeutic areas. 
 
Most anti-TB drugs target enzymes that are essential for biochemical reactions in M. 
tuberculosis and these reactions are vital for bacterial survival. Structural genomics 
encourages scientists to look for other essential enzymes as potential new anti-TB drug 
targets, including extracellular proteins involved in virulence and persistence determinants, 
secreted antigens and proteins involved in iron acquisition (Ahmed and Hasnain, 2004).  
 
Analysis of the M. tuberculosis genome sequence provides important information for the 
identification of new potential drug targets. 
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1.4 Genome of Mycobacterium tuberculosis 
The complete genome of the M. tuberculosis H37Rv reference strain was sequenced in 1998 
(Cole et al., 1998), and re-annotated in 2002 (Camus et al., 2002). This showed that the 
genome of this strain contained 4,411,529 base pairs (bp) and around 4000 genes. It has a 
high guanine + cytosine (G+C) content (65.6%) uniformly throughout the genome. Several 
regions showing higher than average G+C content were detected, and it was found that these 
regions consist of genes which belong to a large gene family that includes the polymorphic 
G+C-rich sequences (PGRSs). One special feature of the genome is that around 250 genes are 
involved in synthesis and metabolism of lipids. They enable the bacteria to synthesize a very 
complex lipid-rich cell wall. Another very unusual feature is the fact that 10% of the coding 
capacity of the genome encodes for two gene families, PE and PPE. PE and PPE genes are 
mostly found in the mycobacteria. About 51% of the genome has arisen through gene 
duplication; and 3.4% of the genome is composed of insertion sequences (IS) and prophages 
(Cole et al., 1998). Three of the most well-known M. tuberculosis gene families have arisen 
through gene duplication, namely the PE, PPE and ESAT-6 gene families. 
 
 
1.5 ESAT-6 gene cluster encoding for Type VII secretion system 
The genome of Mycobacterium tuberculosis contains five copies of the ESAT-6 gene cluster 
referred to as ESX-1, ESX-2, ESX-3, ESX-4 and ESX-5. Each cluster in turn contains 
members of the CFP-10 (Culture Filtrate Protein, 10 kDa) and ESAT-6 (Early Secreted 
Antigenic Target, 6 kDa) gene families, the PE (Proline-Glutamate) and PPE (Proline-
Proline-Glutamate) gene families, secreted, cell-wall-associated subtilisin-like serine 
proteases (mycosins), putative ABC transporters, ATP-binding proteins and other membrane-
associated proteins (Figure 1.1) (Gey van Pittius et al., 2001).  
 
Phylogenetics and comparative genomics analysis suggested that ESAT-6 gene cluster region 
4 is ancestral and that all the other regions were duplicated from it. The five regions evolved 
through duplication which probably took place in the following order: region 3 (Rv0282-
0292) => region 1 (Rv3866-3883c) => 2 (Rv3884c-3895c) => and 5 (Rv1782-1798) 
(demonstrated in Figure 1.1) (N.C. Gey van Pittius, personal communication). 
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encodes for a transmembrane ATPase) (Renshaw et al., 2005). Once the ESAT-6/CFP-10 
complex is recognized by Rv3871, Rv3871 in turn delivers the complex to Rv3870, which 
belongs to the same protein family as Rv3871 (Figure 1.2), whereafter it is translocated to the 
secretion machinery on the cell membrane, probably Rv3877 (which is a multi-
transmembrane protein that might constitute the inner-membrane secretion channel). 
Similarly, EspA (Rv3616c), a gene which is an additional non-ESX-1 gene necessary for 
secretion (acting like ESAT-6), binds to Rv3615c (EspC, acting like CFP-10) prior to 
secretion. Rv3615c was found to be recognized by another cyosolic AAA ATPase (Rv3868) 
(other than Rv3871 and Rv3870) through its C-terminus (the same recognition mechanism as 
CFP-10 with Rv3871) (Champion et al., 2009). EspA was found to bind to CFP-10/ESAT-6 
complex as well. They can be co-secreted via ESX-1 and it is believed that EspA interacts 
with both CFP-10 and ESAT-6 (Callahan et al., 2009). Very surprisingly, without EspA or 
EspC, the ESAT-6/CFP-10 dimer can be produced but not secreted (MacGurn et al., 2005; 
Fortune et al., 2005). Without the expression of ESAT-6/CFP-10, none of the other known 
substrates of ESX-1 is secreted. Similarly, strains lacking EspB, EspC or EspR fail to secrete 
the ESAT-6/CFP-10 dimer (McLaughlin et al., 2007; Xu et al., 2007; Raghavan et al., 2008). 
This implies that the ESX-1 substrates are dependent on one another for secretion. It is 
possible that Type VII substrates are only secreted as multimeric complexes (Abdallah et al., 
2007); alternatively these four substrates might be components of the secretion system and 
form some sort of pilus or extracellular structure (Ize and Palmer, 2006). The Rv3781-
Rv3780 complex could form a hexameric ring structure with a central cavity that propels 
ESX-1 substrates through the secretion channel. The functions of other components of ESX-1 
are more difficult to predict.  
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Figure 1.2 Working model for the ESX-1 secretion system. The secretion of Rv3616c (EspA) is interdependent 
on the presence of ESAT-6/CFP-10 complex. The ESAT-6/CFP-10 complex is recognized by Rv3871 which 
binds to the C-terminal of CFP-10. Rv3871 is situated with the inner membrane (IM) by interacting with 
Rv3870. The translocation channel in the IM is probably formed by Rv3877. It is unknown which protein forms 
the channel in the mycomembrane (MM). The AAA+ chaperone-like protein Rv3868 could be involved in the 
biogenesis of the secretion machinery. The function of MycP1 is essential in the secretion process and one 
substrate, EspB, has been discovered by Ohol and coworkers (taken from Abdallah et al., 2007). 
 
Even though there are five copies of the ESAT-6 gene cluster within the genome of M. 
tuberculosis, these five ESX systems do not complement one another fully, although a small 
degree of partial complementation has been observed. The reason for this might be that each 
one of them has a different signal for their secretion and they also differ in their regulation 
patterns (Champion et al., 2006). They might also have evolved different functions. ESX-1 
genes are downregulated when the culture is starved whereas ESX-2 genes are upregulated 
under these conditions (Betts et al., 2002). ESX-3 is regulated by the availability of zinc and 
iron ions, as part of the ideR and Fur regulon (Rodriguez and Smith, 2003; Maciag et al., 
2007). ESX-4 genes are regulated by the alternative sigma factor SigM (Agarwal et al., 2007). 
Besides regulation differences among these five gene clusters, it was also found that ESX-1, 
ESX-2 and ESX-4 can be disrupted by knockouts, but ESX-3 and ESX-5 cannot, which 
suggests the essentiality of those two clusters for the growth of the culture (Sassetti et al., 
2003). However, it was possible to knock out ESX-3 in M. smegmatis (Siegrist. et al, 2009). 
 
Among the five ESX systems, ESX-1 and ESX-5 are responsible for virulence. The ESX-1 
secretion system can be found in many mycobacteria but ESX-5 is only found in slow-
growing mycobacteria which are mostly pathogenic (Abdallah et al., 2006; Gey van Pittius et 
al., 2006). ESX-1 transports and secrets ESAT-6 and CFP-10 which are potent T-cell 
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antigens from M. tuberculosis (Sorensen et al., 1995). Experimental evidence showed that a 
knockout of ESX-1 in M. tuberculosis attenuates the pathogen and that complementation of 
ESX-1 in the attenuated M. bovis BCG strain makes the bacteria partially regain its virulence 
(Pym et al., 2002). In fact, deletion of any of the genes situated in ESX-1 attenuates M. 
tuberculosis (Guinn et al., 2004). Knock-out mutations of the genes Rv3868-Rv3872 and 
Rv3877 in ESX-1 also abolishes secretion of ESAT-6 and CFP-10 (Lewis et al., 2003; Pym 
et al., 2003; Stanley et al., 2003; Gao et al., 2004; Guinn et al., 2004). Inactivation of esxA 
and esxB, the genes of ESAT-6 and CFP-10 also attenuates M. tuberculosis. However, 
inactivating genes Rv3876 and Rv3873 did not appear to prevent the secretion of ESAT-6 or 
CFP-10 (Brodin et al., 2004; Demangel et al., 2004). The same characteristics were revealed 
in ESX-1 in Mycobacterium smegmatis, where disruption of any of the genes Sm3866, 
Sm3883c, Sm3882c and Sm3869 (except Sm3868) abolished the secretion of SmESAT-6 and 
SmCFP-10 (Converse and Cox, 2005). In the same study, it was found that SmESAT-6 and 
SmCFP-10 were secreted when M. smegmatis was grown in Sauton’s medium but not in 
normal 7H9 medium. The reason for this is unknown (Converse and Cox, 2005). Moreover, 
in spite of the evolutionary distance between M. tuberculosis and M. smegmatis, the M. 
smegmatis secretion system can secrete the M. tuberculosis ESAT-6 and CFP-10 proteins, 
suggesting that substrate recognition is also conserved between the two species. Interestingly 
ESX-1 in non-pathogenic M. smegmatis was found to carry out DNA transfer, i.e. 
conjugation (Coros et al., 2008). ESX-5 is also responsible for virulence like ESX-1 but it 
mostly carries out the transport and secretion of the PE_PGRS and PPE-MPTR proteins 
(Abdallah et al., 2009). ESX-3 is required for growth both in medium under iron-limited 
conditions and macrophages within which the iron is also scarce (Siegrist et al., 2009). This 
study showed a close relationship between ESX-3 and the mycobactin pathway. The authors 
concluded that ESX-3 is essential for mycobactin-mediated iron acquisition. In a study done 
by Serafini and coworkers, it was suggested that ESX-3 encodes a novel iron/zinc uptake 
system or it has a strong effect on mycobacterial cell surface permeability to iron and zinc 
(Serafini et al., 2009). They also proposed that ESX-3 must be secreting some unrecognized 
factors required for the optimal uptake of iron and zinc. It suggests that ESX-3 might be 
involved in zinc and iron homeostasis. The functions of ESX-2 and ESX-4 have not been 
studied in detail because their relationship with pathogenicity is not as strong as that of the 
other three clusters. 
 
 
  
10 
 
1.6 ESAT-6, CFP-10 and their homologs in ESAT-6 gene cluster region 3 
Many studies have been done on the ESAT-6/CFP-10 complex of ESX-1 since ESX-1 has 
been shown to be important for virulence. ESAT-6 and CFP-10 are co-transcribed through a 
single promoter and interact with each other forming a complex (Berthet et al., 1998). The 
direct interaction between ESAT-6 and CFP-10 is very strong (Kd < 1.1x10-8 M) (Renshaw et 
al., 2002; Meher et al., 2006). The elucidation of the molecular structure of the ESAT-6/CFP-
10 1:1 complex revealed that the core of the complex consists of two helix-turn-helix hairpin 
structures formed from two individual proteins, which have an extensive hydrophobic contact 
surface and lie anti-parallel to each other to form a four-helix bundle (Figure 1.3). Both 
proteins have disordered N-termini as well as C-termini, which form long flexible arms at 
both ends of the four-helix bundle core. The surface of this complex has a very uniform 
distribution of positive and negative charge, with no hint of a significant hydrophobic patch 
(Renshaw et al., 2005). There is no significant cleft in the surface of the complex which 
indicates that there is no active site for an enzyme. This suggests that there is no catalytic role 
for this complex. The surface feature of the complex, in fact, suggests a role based on specific 
binding to one or more target proteins, probably in pathogen-host cell signaling. This 
prediction was proven by imaging the interaction of fluor-labeled CFP-10/ESAT-6 complex 
with U937 monocytes. It was confirmed that the CFP-10/ESAT-6 complex mediated the 
binding of fluorescently labeled CFP-10/ESAT-6 complex to the surface of U937 cells and 
that the flexible C-terminal arm of CFP-10 formed an essential part of the cell surface 
receptor binding site. These findings imply that the CFP-10/ESAT-6 complex plays a 
possible signaling role in which binding to cell surface receptors leads to modulation of host 
cell behaviour (Renshaw et al., 2005). CFP-10 dissociates from ESAT-6 when the pH of the 
solution is lowered to acidic levels (pH 4 or 5). These levels are often encountered in the 
phagosome, allowing the binding of ESAT-6 to the membrane and lysing it (CFP-10 does not 
have the same membrane lysis ability) (de Jonge et al., 2007). It is proposed that CFP-10 
might function as a chaperone for ESAT-6. CFP-10 is involved in the transport and 
protection of ESAT-6 until it reaches the phagosomal compartment (de Jonge et al., 2007). 
Derrick and coworkers found that the ESAT-6 protein also induces apoptosis of macrophages 
by activating caspase expression (Derrick and Morris, 2007).  
 
The homologues of CFP-10 and ESAT-6 in ESX-3 are named esxG (Rv0287) and esxH 
(Rv0288). ESAT-6 gene cluster region 3 was proven to be essential for the growth of M. 
tuberculosis, but not for pathogenicity in vivo (Siegrist, et al., 2009). esxH expression was 
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found to be markedly down-regulated in an attenuated strain of M. tuberculosis H37Ra (Rindi 
et al., 1999). Protein esxH is also a potent T-cell antigen strongly recognized in M. 
tuberculosis-infected humans (Skjot et al., 2002). However, studies on esxG have been very 
limited. It was found in short-term culture filtrates of M. tuberculosis in proteomic studies 
(Rosenkrands et al., 2000). Like CFP-10 and ESAT-6, these two genes are also co-operonic 
(Okkels and Andersen, 2004). Moreover, they interact with each other just like the interaction 
between ESAT-6 and CFP-10; however, cross-interaction was not observed (Okkels and 
Andersen, 2004). The same study also found that the ESAT-6 proteins (ESAT-6, CFP-10 and 
esxH) interact directly with PPE68 (Rv3873), and the binding was specific. Apart from this, 
not much research has been done on esxG and esxH. Their structure and function remain 
unknown. 
 
 
Figure 1.3 Solution structure of the CFP-10/ESAT-6 complex. (A) A best-fit superposition of the protein 
backbone for the family of 28 converged structures obtained, with CFP-10 shown in red and ESAT-6 in blue. 
The long flexible C-terminal arms of both proteins are identifiable, as is the propensity to helical structure in this 
region of CFP-10. (B) A ribbon representation of the backbone topology of the CFP-10/ESAT-6 complex based 
on the converged structure closest to the mean, which illustrates the two helix-turn-helix hairpin structures 
formed by the individual proteins. The orientation of the complex is identical to that shown in panel A, with 
CFP-10 in red and ESAT-6 in blue. The helical propensity of the section in the flexible C-terminus of CFP-10 
can be clearly seen in the top right of the figure (Take from Renshaw et al., 2005). 
 
 
1.7 PE and PPE genes and their gene products 
The PE and PPE family proteins are essential components of the ESAT-6 gene clusters 
except for the ancestral region 4. They can also be found outside the ESAT-6 gene clusters. 
The genes encoding PE and PPE proteins are frequently clustered (Gey van Pittius, et al., 
  
12 
 
2006). They are often based on multiple copies of the polymorphic repetitive sequences 
(PGRSs) and major polymorphic tandem repeats (MPTRs), respectively (Figure 1.4). The 
names PE and PPE are derived from the N terminal motifs Pro-Glu (PE) and Pro-Pro-Glu 
(PPE) at positions 8-9, or 8-10, in the amino acid sequences respectively (Gordon et al., 
1999). The PE protein family has 99 members, all of which have a highly conserved N-
terminal domain of about 110 amino acids, followed by a C-terminal segment that varies in 
size, sequence and repeat copy number (Cole, et al., 1998). The sizes of the PE proteins vary 
from 110 (contain N-terminal motif only) to 1500 residues (Cole, et al., 1998). Therefore, 
based on these variations, the PE protein family is divided into three subfamilies. The first 
family containing 29 members only has the PE domain; the second one of 8 members 
contains the PE domain followed by a unique sequence; the third one of 67 members contains 
the PE domain followed by multiple repetitive tandem repeats of Gly-Gly-Ala or Gly-Gly-
Asn, the so-called PGRS (Gordon et al., 1999). The PPE protein family has 68 members and 
also has a conserved N-terminal domain that comprises about 180 amino acids, followed by 
C-terminal segments that vary markedly in sequence and length. There are four subfamilies 
of the PPE protein family (Adindla and Guruprasad, 2003). The largest family has 24 
members, which are characterized by the motif Gly-X-X-Ser-Val-Pro-X-X-Trp between 
position 300 and 350 in the amino acid sequence. The second largest subfamily (23 members), 
also termed as major polymorphic tandem repeat (MPTR) PPE subfamily, contains multiple 
C-terminal repeats of the motif Asn-X-Gly-X-Gly-Asn-X-Gly, encoded by a consensus 
repeat sequence GCCGGTGTTG. The third subfamily (10 members) is characterized by a 
conserved 44 amino acid reside region in the C-terminus comprising of highly conserved 
Gly-Phe-X-Gly-Thr and Pro-X-X-Pro-X-X-Trp sequence motifs (Adindla and Guruprasad, 
2003). The fourth PPE subfamily (12 members) consists of proteins with a low percentage of 
homology at the C-terminus (Gordon et al., 1999). 
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Figure 1.4 Diagrammatic representation of the gene structures of the PE and PPE gene families, showing 
conserved N-terminal domains, motif positions and differences among different subfamilies found in these two 
families (Gey van Pittius et al., 2006). 
 
PE and PPE genes are organized in operons where PE genes are usually (28 out of 41 operons) 
upstream to PPE genes in the genome. Within these operons, the PE and PPE genes are 
separated by less than 90 bp (Tundup et al., 2006 and Strong et al, 2006). Their expression is 
co-operonic where one promoter controls the expression of both PE and PPE genes in the pair. 
Such an arrangement happens frequently in the M. tuberculosis genome. For instance, the 
PPE gene Rv0915c is downstream from PE gene Rv0916c, and they are separated by a 14 bp 
intergenic region (Skeiky et al., 2000); PPE gene Rv1787 is separated from a PE gene 
Rv1788 by 78 bp (Li et al., 2005) and PE gene Rv2431c precedes its PPE gene partner 
Rv2430c by 46 bp (Tundup et al., 2006).  
 
Interestingly, recombinant PE/PPE proteins rRv2431c and rRv2430c form inclusion bodies 
when over-expressed on its own in Escherichia coli, but they appeared in soluble fraction 
when they were co-expressed. There is evidence that they interact with each other similar to 
ESAT-6 and CFP-10 (Tundup et al., 2006 and Strong et al., 2006). They form oligomers 
when alone, but exist as a heteromer when present together (Tundup et al., 2006). 
 
The 3-D structures of individual PE and PPE proteins are difficult to elucidate because of the 
solubility problems described above (Strong et al., 2006; Tundup et al., 2006). The structure 
of this 1:1 complex could only be defined when they are co-expressed and co-purified 
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(Strong et al., 2006). The complex is highly α-helical and it is heterodimeric, containing one 
PE and one PPE protein. The PE protein is a two-helix bundle; together with two of the five 
helices of the PPE protein, they form a four-helix bundle (Figure 1.5). The PE protein is 
composed of two α-helices (residues 8-37 and 45-84) which run anti-parallel to each other, 
connected by a loop (residues 38-44), with both the N and C termini at the top of the complex. 
This PE loop is stabilized by the interactions with helices 2 and 5 of the PPE protein. The 
conserved Pro-Glu (PE) sequence motif is located at the N-terminus of the PE protein 
(residues 8-9). The PPE protein is entirely helical. The conserved Pro-Pro-Glu (PPE) 
sequence motif is located near the N-terminus of the PPE protein (residue 7-9). Helices α2 
(residues 21-53) and α3 (residues 58-103) of the PPE protein run anti-parallel and form the 
interaction interface with the PE protein (Strong et al., 2006). 
 
 
Figure 1.5 Crystal structure of the M. tuberculosis PE/PPE protein complex using the Rv2431c/Rv2430c pair as 
an example. (a) Surface representation of the PE/PPE protein complex. The PE protein Rv2431c is shown in red 
and the PPE protein Rv2430c is in blue. (b) The longitudinal view of PE/PPE protein complex. (c) Ribbon 
diagram of the PE/PPE protein complex. (d) Interface hydrophobicity of the PPE and PE proteins. The strength 
of hydrophobicity increases from the colour blue to red (taken from Strong et al., 2006). 
 
The PE and PPE proteins are predicted to carry out interactions among cells and have 
immunological importance. The PE-PGRS protein encoded by Rv1818c is able to mediate 
cell-cell adhesion because the disruption of this gene causes a great reduction of bacterial 
clumping (Brennan et al., 2001). Moreover, the phagocytosis of such mutant cells by 
macrophages was also reduced (Brennan et al., 2001). Another PE-PGRS protein, Rv1759c is 
able to bind fibronectin and could thus mediate bacterial attachment to host cells (Espitia et 
al., 1999). Immunization with the PE domain of PE-PGRS protein, Rv1818c, was proven to 
induce Th1-type responses that were not found when the complete PE-PGRS protein was 
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used. Instead, the PGRS part of the protein elicited antibodies and suppressed the Th1 
response induced by the PE domain (Delogu and Brennan, 2001). It was found that there is 
some similarity between structural proteins of insects, such as silk, and the PGRS domain. 
This suggests that the role of the PE-PGRS proteins may be purely structural (Banu et al., 
2002). Some PE proteins may be essential for virulence. Mutations of two of the PE_PGRS 
genes of Mycobacterium marinum, which are the homologues of M. tuberculosis Rv3812 and 
Rv1651c, rendered M. marinum strains incapable of replication in macrophages and also 
resulted in decreased persistence in granulomas (Ramakrishnan et al., 2000).  
 
As mentioned previously, the PPE proteins of the MPTR subfamily also shows variability, 
however, not much evidence has been found concerning their possible functions. One 
member of the PPE protein family, Rv1917c, was shown to be cell-wall-associated and 
surface-exposed (Sampson et al., 2001). PPE68 (Rv3873) was also found to be associated 
with the cell envelope (Okkels et al., 2003). The PPE family protein Rv2608, which is a 
member of the major polymorphic tandem repeat (MPTR) subfamily, was found to elicit high 
humoral responses and low T-cell responses in TB patients (Chakhaiyar et al., 2004). The 
PPE gene Rv0951c was found to develop both CD4 and CD8 specific T cell responses and 
could provide protection against M. tuberculosis comparable to M. bovis BCG vaccination 
when immunized in C57BL/6 mice (Skeiky et al., 2000). Overall, it can be concluded that 
both the PE_PGRS and PPE-MPTR proteins may act as variable surface antigens (Banu et al., 
2002). 
 
Besides the functions of individual PE and PPE family proteins that have been discovered so 
far, the PE/PPE protein complex was also found to elicit humoral and cell mediated immune 
responses. The PE25/PPE41 (Rv2431c/Rv2430c) complex induces significant B cell 
responses in sera derived from TB patients (Tundup et al., 2008). The complex may play a 
different role other than eliciting immune responses. When the protein structure of the PE and 
PPE complex was elucidated, it was found that an apolar stripe appears along one side of the 
complex, suggesting a docking site for another protein (Figure 1.6) (Strong et al., 2006). 
Strong’s group used the metaserver ProKnow to predict the function of the PE/PPE complex. 
ProKnow infers functions for proteins based on sequence homology and structural similarity 
to other proteins of known function in the Protein Data Bank. The possible functions were 
expressed as Gene Ontology (GO) terms, each given with a Bayesian weight. The highest 
scoring GO term for biological process of this PE/PPE protein complex is “signal 
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transduction” with a probability of 75%. A similar result was concluded by using a 
combinatorial extension programme which identified protein structures with similar 3-D 
structures (Strong et al., 2006). This predicted role of “signal transduction” still needs to be 
proved experimentally. 
 
 
Figure 1.6 Surface hydrophobicity of the PE/PPE protein complex. One face of the PE/PPE complex surface has 
a stretch of apolar amino acids that may suggest a putative binding surface for other protein–protein interactions. 
Interestingly, this hydrophobic stretch overlaps with the conserved polyproline stretch and conserved PPE 
region of the complex. (Strong et al., 2006) 
 
Importantly PE-PGRS and PPE proteins, like ESAT-6 and CFP-10 acting as the substrates of 
ESX-1, were also found to be the substrates of ESX-5 secretion system (Abdallah et al., 
2009). It is not sure whether the PE and PPE proteins in other regions (ESX-2 and ESX-3) 
happen to be the substrates of their regions as well. 
 
 
1.8 Mycosin, a subtilisin-like serine protease 
Another protein family associated with the ESX gene cluster is the mycosins. The five 
mycosins belong to a family of transmembrane serine proteases. They contain a conserved 
catalytic triad (Asp, His, Ser), which is typical for the proteases of the subtilisin family 
(Brown et al., 2000). One member, mycosin 1, whose gene is situated 3700 bp from the RD1 
deletion region in the genome of the attenuated vaccine strain M. bovis BCG, was later 
confirmed to be a cell wall-associated extracellular protein expressed during infection of 
macrophages (Dave et al., 2002). Mycosins are believed to modify the substrates upon their 
secretion (Gey van Pittius, et al., 2001) or regulate the secretion and virulence (Ohol et al., 
2010). The substrates for the mycosins, however, have never been identified until a recent 
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study in which Ohol and coworkers found that EspB (which is an ESX-1 substrate) is a target 
of MycP1 in vitro and in vivo. Questions were soon raised about this discovery because EspB 
is only found in ESAT-6 gene cluster region 1 and thus not present in any of the other 4 ESX 
regions. Since the five mycosins evolved from duplication and are very conserved, their 
substrates are presumably from ESAT-6 gene clusters regions, such as ESAT-6, CFP-10 or 
even PE and PPE proteins. Unfortunately, studies on the mycosins are very limited. So far 
their structures, substrate specificity, and functions have not been revealed. 
 
 
1.9 Potential drug target candidate 
The mycosins are the most conserved enzymes encoded within the five virulence-associated 
ESAT-6 gene clusters and as such they are potential drug target candidates (Gey van Pittius, 
et al., 2006). Their functions are unknown, but it is known that they are vital for the 
pathogenicity of M. tuberculosis. Their actual substrates have also not been identified or fully 
understood. Among the five of them, mycosin-3 (MycP3) was the only one found to be 
essential for M. tuberculosis growth and the gene cluster containing it could not be knocked 
out in this organism. Mycosin-3 thus provides a very important new potential drug target for 
treating TB. 
 
 
1.10 Catalytic characteristics and stability of novel subtilisin-like serine proteases 
Since there are not much known about mycosins, it is useful to look at their homologues in 
other organisms. It is known that MycP3, together with the other four mycosins, belong to the 
subtilase family (the superfamily of subtilisin-like serine proteases). It is hypothesized that 
the mycosins have similar characteristics to other subtilases even though previous protease 
substrate identification experiments were not successful (Dave et al., 2002; N.C. Gey van 
Pittius, personal communication). 
 
Subtilases can be found in numerous prokaryotes and eukaryotes such as gram-positive 
bacteria, slime molds, plants, insects, nematodes, mollusks, amphibians, fish, mammals, and 
even viruses. According to the sequence homology of their catalytic domains, this 
superfamily can be divided into 6 families namely subtilisin (A), thermitase (B), Proteinase K 
(C), lantibiotic peptidase (D), Kexin (E) and pyrolysin (F). Among all of them, only four 
residues in the catalytic region are conserved, including the catalytic triad residues Asp (D) 
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32, His (H) 64, Ser (S) 221, and a single glycine residue (G) 219. The substrate binding 
region of the subtilase proteases was presented diagrammatically by Siezen and coworkers 
(Figure 1.7).  
 
The substrate/inhibitor binding pocket shown in Figure 1.7 accommodates six amino acid 
residues (P4, P3, P2, P1, P1’ and P2’). The specificity largely depends on the interactions 
between P4-P1 residue side chains and S4-S1 clefts respectively. S1 and S4 binding sites in 
subtilisin (A) and thermitase (B) are large and hydrophobic, which explains the broad 
specificity of both enzymes with a preference for aromatic or large nonpolar P1 and P4 
substrate residues (Gron et al., 1992). Most of the subtilases have binding regions similar to 
those in subtilisin and thermitase so they should also have a broad specificity and can be 
considered as general-purpose proteases. Modeling and engineering studies have shown that a 
high density of negative charge at the substrate binding site, and in particular at S1, S2 and 
S4 sites, is responsible for high substrate selectivity (Lipkind et al., 1995; Perona et al., 1995; 
Siezen et al., 1994). This suggests that if there are more electrostatic interactions between the 
binding pocket and the substrate residues instead of hydrophobic interactions, the subtilase is 
going to have a narrower selectivity for the substrate (Siezen and Leunissen, 1997). 
 
 
Figure 1.7 Schematic representation of substrate/inhibitor (bold lines) binding to a subtilisin-like serine protease. 
Side chains of the P4-P2’ residues are shown as large spheres; position of the enzyme residues that may interact 
with these P4-P2’ side chains are shown surrounding the binding sites (S1, S2, S2’ S4). Hydrogen bonds 
between enzyme and substrate/inhibitor are shown as dotted lines, and the scissile bond is shown by a jagged 
line. Catalytic residues D32, H64, and S221, and oxyanion-hole residue N155 are indicated (taken from Siezen 
et al., 1997). 
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Calcium ions are essential for the stability and activity of subtilases. There are usually four 
calcium binding sites in a typical subtilase indicating the importance of divalent ion for 
structural stability (Siezen and Leunissen, 1997). Disulfide bonds are much less important 
because subtilases do not rely on highly conserved disulfides for stabilization, and in fact, 
most subtilases do not have any disulfides (Siezen and Leunissen, 1997).  
 
 
1.11 Methods to screen protease specificity 
As described above, the mycosins are grouped under the domain of subtilases based on 
sequence similarity. However, their protease activities seem to be different from other 
members of these families and they seem to have very narrow substrate selectivity. In order 
to elucidate their substrates, protease specificity screening experiments need to be conducted. 
Several methods for identifying protease substrates were summarized by Agard and 
coworkers in 2009.   
 
The first method which can be employed is two-dimensional differential gel electrophoresis 
(2D-DiGE), which separates proteins from a cell lysate into resolvable spots. The proteins in 
the first dimension resolve based on their pI value; the second dimension is run under the 
principle of SDS-PAGE thus the proteins separate based on size. Comparative staining 
reveals differences between proteolyzed and control samples which can be analyzed by mass 
spectrometry (MS) (Tonge et al., 2001) (Figure 1.8A). A modified 2D-PAGE method 
employs SDS-PAGE on both dimensions with an intermediate in-gel proteolysis treatment 
step to identify protease targets (Shao et al., 2007). The proteins which migrate off the 
diagonal in the second dimension SDS-PAGE gel are probably the substrates (Figure 1.8B). 
A one-dimensional SDS-PAGE-based method called PROTO-MAP was developed during 
Jurkat cell apoptosis (Dix et al., 2008). In this method, apoptotic and control cell lysates were 
run parallel on one SDS-PAGE gel. The gel lanes were sliced into bands (Figure 1.8C). After 
in-gel trypsin digestion, the proteins in each band were identified by liquid chromatography-
mass spectrometry (LC-MS), and quantified by spectral counting. Proteins from apoptotic 
cells that decreased in intensity or shifted from higher to lower apparent molecular weight 
were presumed to be caspase substrates. 
 
Another approach for screening protease substrate specificity is to use a short peptide library 
where short peptides with 3 or 4 residues are constructed in a completely random manner 
  
20 
 
with all 20 amino acids (Thomas et al., 2006). Usually there are several glycine residues on 
each side of the tri- or tetra-peptides, and a donor group and a quencher group on each end 
respectively are paired and this pair is in a quenched state prior to cleavage. When the short 
peptide is cleaved by the protease, the donor group will leave the quencher group resulting in 
the emission of fluorescence. By monitoring the increase of fluorescence over time, the 
protease specificity over certain peptides will be elucidated and the kinetic data can also be 
generated. Using this method, cleavage sites of the protease can be elucidated. The substrate 
specificity of MycP1 was recently identified by such an approach using a library of 
fluorogenic tetrapeptide substrates (Ohol et al., 2010). 
 
Knowledge about the substrate specificity of mycosin-3 and the sequences of the protease 
recognition and cleavage sites could be used to compare this with the known substrates of 
subtilases in order to find potential protease inhibitors. 
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Figure 1.8 (A) 2D DiGE: A control and a proteolyzed lysate are fluorescently labeled, mixed and analyzed by a 
2D-gel. Spots with unequal fluorescence ratios are picked up as potential substrates for subsequent MS analysis; 
(B) 2D SDS-PAGE: a lysate is resolved on one SDS-PAGE first, then in-gel treated with protease of interest. 
After the 2nd SDS-PAGE analysis, any spots below the diagonal are identified as substrate; (C) PROTO-MAP: 
control and proteolyzed cell lysates are analyzed side-by-side via SDS-PAGE. The gel is cut into bands, 
trypsinized, and peptides are identified by LC-MS. For each protein, peptides are analyzed by peptographs, 
which are analysis tools that display the sequence coverage and intensity in each band, revealing the 
approximate site(s) and extent of cleavage. (Taken from Agard and Wells, 2009) 
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1.12 Problem Statement 
The ESAT-6 gene cluster has duplicated five times during evolution. The conservation of the 
gene clusters over time shows the importance and essentiality of the five secretion systems 
towards the survival of mycobacteria. The mycosins are the enzymes in the ESAT-6 gene 
cluster with the most conserved sequences. Among the five of them, mycP3 is essential for 
the growth of the organism, and an ESAT-6 gene cluster region 3 knock-out strain can not be 
generated. Studying the functions and elucidating the substrates of mycP3 will aid in the 
understanding of the mechanisms of the ESX-3 secretion system. This could lead to the 
design of new drugs to target the system in M. tuberculosis. 
 
 
1.13 Hypothesis 
We hypothesize that the substrates of mycosin-3 in Mycobacterium tuberculosis are the 
secreted proteins encoded by ESAT-6 gene cluster 3 (ESX-3), namely PE5 and PPE4, or 
esxG and esxH. 
 
 
1.14 Aims of the project 
1. To clone the mycosin-3 (with/without hydrophobic tail), PE5, PPE4, combined PE5 
and PPE4, esxG , esxH, and combined esxG and esxH genes in an E. coli expression 
vector 
2. To express the proteins in E. coli as His-tagged fusion proteins 
3. To clone the genes of mycosin-3 without hydrophobic tail, PE5, PPE4, combined PE5 
and PPE4, esxG, esxH, combined esxG and esxH in a mycobacterial expression 
vector 
4. To express the proteins in M. smegmatis as His-tagged fusion proteins 
5. To purify all His-tagged fusion proteins using nickel columns 
6. To conduct protease assays using purified mycosin-3 and selected potential substrate 
proteins PE5, PPE4, esxG and esxH in an appropriate buffer condition 
7. To identify the substrate of mycosin-3 by conducting 2D-PAGE and Mass 
Spectrometry 
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Chapter 2 Materials and Methods 
 
2.1 Strains and Plasmids  
 
The Escherichia coli expression vector pET-28a (Novagen, Germany), as well as the 
Mycobacterium smegmatis expression vectors p19Kpro (Imperial College Medical School, 
UK) and pDMN1 (a kind gift from Dr. Ros Chapman, University of Cape Town, South 
Africa) were selected as the vectors for expressing target fusion proteins. The plasmid DNA 
maps of these expression vectors are given in Addendum 6.1. The reason for using two 
different mycobacterial expression vectors was because the strengths of the promoters of 
these two expression vectors are different. Vector pDMN1 contains the Psmyc promoter which 
is a much stronger promoter than the 19 kDa promoter (P19kDa) in vector p19Kpro. Vector 
pDMN1 was used in the case where p19Kpro could not express the protein of interest in 
sufficient amounts. E. coli XL-1 blue strain was used for gene manipulation for all three 
expression vectors. E. coli BL21 (DE3) pLysS strain was used for recombinant fusion protein 
expression for the pET-28a expression vector. BL21 (DE3) pLysS is lysogenic for λ-DE3, 
which contains the T7 bacteriophage gene I, encoding T7 RNA polymerase under the control 
of the lac UV5 promoter (Studier and Moffatt, 1986). BL21 (DE3) pLysS also contains a 
plasmid, pLysS, which carries the gene encoding T7 lysozyme. T7 lysozyme lowers the 
background expression level of target genes under the control of the T7 promoter but does 
not interfere with the level of expression achieved following induction by IPTG (Studier and 
Moffatt, 1986). Therefore, BL21 (DE3) pLysS is an ideal strain of E. coli for protein 
expression compared to XL-1 blue strain. M. smegmatis mc2155 strain was used for 
recombinant fusion protein expression for the p19Kpro and pDMN1 expression vectors. 
 
Electro-competent XL1 cells were used for recombinant plasmid DNA transformation and 
they were prepared as follows:  Fresh XL1 single colonies were inoculated into 50 ml Luria 
Bertani (LB)-tetracycline (50 µg/ml) broth and incubated overnight at 37°C. The next 
morning, 20 ml of the overnight culture was re-inoculated into 2 L LB-tetracycline broth and 
grown at 37°C with constant shaking until the OD600nm reached 0.6. The cells were harvested 
by centrifugation at 4000 xg for 10 min at 4°C, and the pellet was resuspended in a volume of 
ice cold sterile 10% glycerol equal to the original culture volume. The resuspension was 
centrifuged again at the same conditions as previously and the washing step was repeated. 
Thereafter, the supernatant was carefully poured off and the cells were resuspended in the 
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volume of glycerol remaining in the centrifuge bottle. The cells in all centrifuge bottles were 
pooled in a 50 ml sterile centrifuge tube and spun at 4000 xg at 4°C for 10 min. The 
supernatant was poured off and the pellet was resuspended in 2–3 ml of 10% glycercol. The 
competent cells were aliquoted into eppendorf tubes (100 µl per tube), snap frozen in liquid 
nitrogen and stored at -80°C. 
 
Electro-competent M. smegmatis was used for recombinant M. smegmatis expression vector 
transformation. They were prepared as follows: One liter 7H9 broth was prepared by mixing 
4.7 g 7H9 powder (Becton Dickinson, USA) in 970 ml H2O, supplemented with 10 ml filter-
sterilized 20% Tween 80 (Sigma, Germany), 10 ml filter-sterilized 50% glucose (Merck, 
Germany) and 10 ml filter-sterilized 50% glycerol (Merck, Germany). One ml of M. 
smegmatis stock culture was inoculated into 100 ml 7H9 broth and incubated overnight at 
37°C. As soon as the OD600nm reached 0.5, the overnight culture was incubated on ice for 1 
hour. Cells were harvested by centrifugation at 4000 xg at 4°C for 10 min. The supernatant 
was discarded and the pellet was washed with 50 ml 10% glycerol after which cells were 
collected again by centrifugation as described previously. The washing step was repeated 
once and the pellet was re-suspended in 4 ml of 10% glycerol. Finally, the fresh electro-
competent M. smegmatis cells were snap-frozen at 200 µl per aliquot. 
 
 
2.2 Primer Design 
 
Genes encoding mycosin-3 (mycP3, Rv0291), PE5 (Rv0285), PPE4 (Rv0286), esxG 
(Rv0287), and esxH (Rv0288) were selected for cloning. The primers designed for cloning 
purposes are given below. As PE5 and PPE4 are co-operonic in the genome, it was decided to 
clone both genes together into the three expression vectors. esxG and esxH are also co-
operonic and the same strategy was followed for these genes. Pairs of primers were designed 
for PCR amplification of the genes into the three different expression vectors pET-28a, 
p19Kpro and pDMN1 (See Table 2.1, Table 2.2 and Table 2.3).  
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Table 2.1 Sequences of primers designed for cloning genes into pET-28a expression vector. 
Genes Sense primer Anti-sense primer 
Mycosin-3 
without 
hydrophobic tail 
5’-CCATGGATGCGTGCAGCGTCT-
3’ 
5’CTCGAGTTGCCAGGTCAGGGCC-3’ 
Mycosin-3 with 
hydrophobic tail 
5’-CCATGGATGCGTGCAGCGTCT-
3’ 
5’-
CTCGAGTTCGGTGGGCTCCCTTCG-3’ 
PE5 5’-
CCATGGTTACGTTGCGAGTGGTT-
3’ 
5’-CTCGAGCACGACCCCGTACGT-3’ 
PPE4 5’-
CCATGGTTCCCATCTGGATGGC-3’ 
5’-
CTCGAGCTTGCTGTCGTGCGGTAAG-
3’ 
Combined PE5 
and PPE4 
Same as PE5 sense primer Same as PPE4 anti-sense primer 
esxG 5’-CCATGGTTAGCCTTTTGGATGC-
3’ 
5’-CTCGAGGGTATAGGTCGACGCG-
3’ 
esxH 5’-
TCATGACTTCGCAAATCATGTAC-
3’ 
5’-CTCGAGGCCCCATTTGG-3’ 
Combined esxG 
and esxH 
5’-
TCATGATTAGCCTTTTGGATGCTC-
3’ 
5’-CTCGAGGCCCCATTTGGC-3’ 
 
All sense primers contained NcoI restriction sites (5’-CCATGG-3’) except the ones for esxH 
and combined esxG and esxH, where the BspHI restriction site (5’-TCATGA-3’) was used 
instead. The reason for this was because the gene sequence of esxH contains an NcoI site 
which could thus not be used in the primer. BspHI was used so that the cloned genes could be 
restricted intact and it generates identical overhang termini to NcoI. Since the NcoI restriction 
site contains a start codon ATG, two nucleotide residues were introduced between the 3’ end 
of the restriction site and the 5’ end of the gene so that the cloned genes would be in frame 
inside the expression vector. All anti-sense primers contained an XhoI restriction site (5’-
CTC GAG-3’). 
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Table 2.2 Sequences of primers designed for cloning genes into the p19Kpro expression 
vector. 
Genes Sense primer Anti-sense primer 
Mycosin-3 
without 
hydrophobic tail 
5’-GGATCCAGGCGGAGAACAAA 
TGGGTGCGTGCAGCGTCTC-3’ 
5’-ATCGATTTAGTGGTGGTGGTGG 
TGGTGTTGCCAGGTCAGGGCCG-3’ 
PE5 5’-GGATCCAGGCGGATCAGTCA 
TGACGTTGCGAGTGGTTCC-3’ 
5’-
ATCGATTTAGTGGTGGTGGTGGTG
G 
TGGCCCACGACCCCGTACGTAGC-
3’ 
PPE4 5’-
GATATCAGGCGGACTGAGCATG 
GCCGCGCCCAT-3’ 
5’-
ATCGATTTAGTGGTGGTGGTGGTG
GT 
GCTTGCTGTCGTGCGGTAAG-3’ 
Combined PE5 
and PPE4 
Same as PE5 sense primer Same as PPE4 anti-sense primer 
esxG 5’-
GGATCCAGGCGGAGATGTTATG
A 
GCCTTTTGGA-3’ 
5’-
ATCGATTTAGTGGTGGTGGTGGTG
GT 
GGAACCCGGTATAGGTCGACG-3’ 
esxH 5’-
GGATCCAGGCGGACTTGTGATG
TC 
GCAAATCATGTACAACTACCCC
G-3’ 
5’-
ATCGATTTAGTGGTGGTGGTGGTG
GT 
GGCCCCATTTGGCGGCTTCGG-3’ 
Combined esxG 
and esxH 
Same as esxG sense primer Same as esxH anti-sense primer 
 
The mycobacterial expression vector p19Kpro does not contain a ribosomal binding site (rbs), 
a start codon (ATG), a 6 x Histidine tag or a stop codon. Thus, in all the sense primers except 
the ones for PE5, PPE4 and the combination of the two, a BamHI restriction site (5’-
GGATCC-3) was designed at the 5’ end, followed by a rbs “AGGCGGA” (Table 2.2). Six 
nucleotides were incorporated between the rbs and the start codon. For the sense primers of 
PE5, PPE4 and the combined PE5 and PPE4, an EcoRV restriction site was used since the 
genes for PE5 and PPE4 contain BamHI restriction sites within their sequences. In all anti-
sense primers, a 6x GTG sequence of which the compliment sequence encodes a 6x His tag 
was designed after the gene sequence, followed by a stop codon and a ClaI restriction site 
(5’-ATCGAT-3’). 
 
The mycobacterial expression vector pDMN1 contains a start codon “ATG” 19 base pairs 
upstream from a HindIII restriction site. All sense primers thus contained a 5’ end HindIII 
restriction site, as well as 2 nucleotides in between the start codon of the gene and the 3’ end 
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of the HindIII restriction site in order for the gene to be cloned in frame (Table 2.3). All anti-
sense primers contained a complimentary 6 x Histidine sequence and a stop codon “TGA”. 
 
Table 2.3 Sequences of primers designed for cloning genes into pDMN1 expression vector. 
Genes Sense primer Anti-sense primer 
Mycosin-3 
without 
hydrophobic tail 
5’-
AAGCTTTTCGCGGTGCGTGCA 
GCGTCTCCGGTGTTATCCCGGG
C-3’ 
5’-GTTAACTCAGTGGTGGTGGTG 
GTGGTGTTGCCAGGTCAGGGCCG
C-3’ 
PE5 5’-
AAGCTTTTATGACGTTGCGAGT
G 
GTTCCGGAGGGGCTGGCCGCAG
-3’ 
5’-GTTAACTCAGTGGTGGTGGTG 
GTGGTGGCCGCCCACGACCCCGT
AC-3’ 
PPE4 5’-
AAGCTTTTATGGCCGCGCCCAT
CT 
GGATGGCTTCGCCGCCGGAGG-
3’ 
5’-GTTAACTCAGTGGTGGTGGTG 
GTGGTGCTTGCTGTCGTGCGGTAA
G-3’ 
Combined PE5 
and PPE4 
Same as PE5 sense primer Same as PPE4 anti-sense primer 
esxG 5’-
AAGCTTTTATGAGCCTTTTGGAT
G 
CTCATATCCCACAGTTGGTGG-3’ 
5’-
GTTAACTCAGTGGTGGTGGTGGT
G 
GTGGAACCCGGTATAGGTCGA-3’ 
esxH 5’-
AAGCTTTTATGTCGCAAATCAT
GT 
ACAACTACCCCGCGATGTTG-3’ 
5’-
GTTAACTCAGTGGTGGTGGTGGT
G 
GTGGCCGCCCCATTTGGC-3’ 
Combined esxG 
and esxH 
Same as esxG sense primer Same as esxH anti-sense primer 
 
 
 
2.3 Polymerase Chain Reaction 
 
All oligonucleotide primers were purchased from Whitehead Scientific (Pty) Ltd, South 
Africa. Lyophilized primers were dissolved in TE (Tris-EDTA) buffer (10 mM Tris, 1 mM 
EDTA, pH 8.0) so that the final concentration of the oligonucleotide stock was 100 µM. The 
working concentration of the oligonucleotide was 10 µM. For each PCR experiment (one 
tube, 25 µl in volume), 14.8 µl DNase-free water (Promega, USA), 2.5 µl 10x buffer 
containing MgCl2(Roche, Switzerland), 1 µl dNTP (Promega, USA), 0.2 µl Taq polymerase 
(Roche, Switzerland), 5 µl 5x GC solution (Roche, Switzerland), 0.5 µl of forward and 
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reverse primer respectively and 0.5 µl M. tuberculosis H37Rv reference strain genomic DNA 
were added. The PCR programme was set up as follows, stage 1: 95°C for 15 minutes; stage 
2 (which was repeated 40 times): 94° for 30 seconds, 60°C for 30 seconds and 72°C for 1 
minute; stage 3: 72°C for 10 minutes; and stage 4: 4°C for 10 minutes. After the PCR 
amplifications were finished, the PCR products were subjected to agarose gel electrophoresis 
for separation and ethidium bromide staining for visualization under the ultraviolet (UV) light 
(Aaij and Borst, 1972). 
 
 
2.4 Cloning of the Genes into the Expression Vectors 
 
2.4.1 Cloning of the genes into the pGEM-T Easy cloning vector 
 
The PCR products were separated on a 1% [w/v in TAE (Tris-Acetate-EDTA) buffer] 
agarose gel by electrophoresis at 100 volts for 70 min. For a liter of 50x TAE buffer, 242g 
Tris, 57.1 ml glacial acetic acid, and 100 ml 0.5 M EDTA were mixed; the pH was adjusted 
to 8.0 and the volume was made up to 1 liter. The DNA molecules were stained inside the gel 
with 0.001 mg/ml (w/v) ethidium bromide (Sigma, Germany) [stock solution 10 mg/ml 
(w/v)]. DNA bands of appropriate sizes were cut out of the agarose gel. The DNA was 
purified from the agarose gel using the Wizard® SV Gel and PCR Clean-Up System 
(Promega, USA).  
 
The concentrations of the PCR products after the purification were quantified by 
NanoDrop®(WhiteSci, South Africa). Ligations of the PCR products into the pGEM-T Easy 
vectors were carried out in a molar ratio of 3:1. The formula used for calculating the volume 
of DNA added in one ligation reaction is as follows: (ng of vector × kb size of insert) × 
(insert : vector molar ratio) = ng of insert × kb size of vector. Using the PCR product of 
Rv0285 (PE5) as an example, the amount of insert added in one ligation reaction was (50 ng 
of pGEM-T Easy vector × 0.311 kb) × 3 / 3 kb = 15.55 ng of Rv0285 PCR product. The same 
method was applied to the other types of PCR products. The ligations were carried out at 4°C 
overnight. 
 
An electroporator (Biorad, USA) was used for transforming the recombinant pGEM-T Easy 
constructs into electrocompetent E. coli XL1 cells. One microliter of ligation mix containing 
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the recombinant DNA, together with 15 µl sterile 10% glycerol was mixed with 50 µl of XL1 
competent cells and transferred into a pre-chilled electroporation cuvette (Bio-Rad, USA). 
Electroporation was carried out at 2.5 kV with 200 ohms resistance. The time constant was 
3.9 s. 
 
After electroporation, 600 µl of Super Optimal Broth with glucose (SOC) medium [2% 
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4·7H2O and 20 mM glucose (Merck, Germany)] was added to the cuvette. The cells 
and the medium were mixed and transferred to a sterile eppendorf tube, after which it was 
incubated in a shaking 37°C incubator for 60 min. An aliquot of 75 µl of the cells were plated 
out on LB-ampicilin (100 ng/µl, Roche, Germany) plates which were previously treated with 
100 µl of 0.1 mM IPTG (Invitrogen, USA) and 100 µl of 20 mg/ml X-gal (Roche, Germany) 
to enable blue/white colony selection. The plates were incubated overnight at 37°C. White 
colonies were picked and used in colony PCR to confirm the presence of the inserts and the 
success of the pGEM-T Easy cloning. During colony PCR, the picked colonies acted as the 
template DNA and were mixed with the PCR reaction mix for the amplification reaction. 
 
 
2.4.2. Cloning of inserts into expression vectors 
 
Colonies confirmed to contain the appropriate inserts in the recombinant pGEM-T Easy 
constructs were inoculated into 5 ml LB+Ampicilin broth and incubated overnight at 37°C. 
Recombinant plasmid DNA was isolated from the mini-cultures using the Wizard® SV Plus 
Miniprep DNA Purification System (Promega, USA). The isolated recombinant vector was 
double digested with NcoI/BspHI and XhoI (Fermentas, USA) for cloning of the insert into 
the pET-28a expression vector, BamHI/EcoRV and ClaI (Roche, Germany) for cloning of the 
insert into the p19Kpro expression vector, and HindIII (Roche Germany) and HpaI 
(Fermentas, USA) for cloning of the insert into the pDMN1 expression vector. 
 
The digested reaction mix was run on a 1% agarose gel and the inserts were cut out of the 
agarose gel and purified as previously described. The inserts were dephosphorylated using 
shrimp alkaline phosphatase (SAP) (Roche, Germany) by incubation at 37°C for 45 min. SAP 
was deactivated by incubation at 65°C for 15 min, and the treated inserts were ligated with 
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double-digested expression vectors using T4 DNA ligase (Promega, USA). Ligation reactions 
were carried out at 4°C overnight. 
 
An aliquot of 1.5 µl of the ligation mix was used for electroporation. All the cells used for 
electroporation were plated onto LB agar plates with an appropriate antibiotic added 
[Kanamycin (Sigma, Germany) for pET-28a and pDMN1, 30 ng/µl; Hygromycin (Invitrogen, 
USA) for p19Kpro, 50 ng/µl]. The plates were incubated at 37°C overnight. Colony PCR was 
applied to check whether the colonies grown on the plates contained the insert DNA. Clone 
verification was also done by plasmid DNA sequencing with the concentration of plasmid 
DNA sample at 100 ng/µl (DNA Sequencing Facility at Stellenbosch University). 
 
 
2.5 Test Expression and Protein Purification 
 
2.5.1 Test Expression of the pET-28a E. coli expression vector constructs in the E. coli BL21 
(DE3) strain 
 
Recombinant expression vector pET-28a containing insert DNA of mycosin-3 with 
hydrophobic tail, mycosin-3 without hydrophobic tail, PE5, PPE4, combined PE5 and PPE4, 
esxG, esxH, and combined esxG and esxH were all electroporated into BL21 (DE3) E. coli 
(Promega, USA) electro-competent cells. Preparation of BL21 (DE3) eletro-competent cells 
and electroporation conditions were the same as that of XL1 cells described previously. The 
BL21 (DE3) E. coli transformants containing specific recombinant DNA were inoculated into 
5 ml Rich Broth (1% tryptone, 0.5% yeast extract, 1% sodium chloride, 0.1% glucose) and 
incubated at 37°C overnight. The following day, a 500 µl aliquot from the 5 ml culture was 
re-inoculated into 9 conical flasks individually, each of which contained 50 ml Rich Broth, 
and incubated at 37°C. Upon reaching OD600nm ~ 0.6, IPTG was added to 3 sets of 3 conical 
flasks to a concentration of 0.25 mM, 0.5 mM, and 1 mM respectively. After the addition of 
IPTG, expression was started by incubating the 9 flasks at three different temperatures (24°C, 
30°C and 37°C) (See Table 1.4). The expression was allowed to carry on for 4 hours. 
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Table 2.4 Method of Test Expression of pET-28a in BL21 (DE3) E. coli strain, same amount 
of inoculant was made for each flask 
 24°C 30°C 37°C 
[IPTG] = 0.25 mM Flask1 Flask2 Flask3 
[IPTG] = 0.5 mM Flask4 Flask5 Flask6 
[IPTG] = 1 mM Flask7 Flask8 Flask9 
 
The protein-expressing culture was harvested by centrifugation at 4000 xg at 4°C for 15 min. 
The supernatant was discarded and the pellet was stored at 80°C. The pellets containing His-
tagged fusion proteins were treated subsequently using the MagneHisTM Protein Purification 
System (Promega, USA) for small scale His-tagged fusion protein purification according to 
the manufacturer’s instructions. The samples of purified His-tagged proteins were analyzed 
by SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE, Laemmli, 1970) (see Section 
2.3.3.1 for SDS-PAGE preparation). The polyacrylamide gel was stained by either 
Coomassie blue stain or Silver stain (see section 2.3.3.2 for gel staining methods). Optimal 
expression conditions were scored by the intensity of the protein band on the stained SDS-
PAGE gel. These optimal conditions were subsequently applied for the protein expression of 
large scale His-tagged fusion protein purification using the Ni-NTA Superflow column 
(Qiagen, Germany) (see Section 2.5.4). 
 
2.5.2. Test Expression of the p19Kpro and pDMN1 mycobacterial expression vector 
constructs in M. smegmatis mc2155  
 
Recombinant expression vectors p19Kpro and pDMN1 containing insert DNA of mycosin-3 
without hydrophobic tail, PE5, PPE4, combined PE5 and PPE4, esxG, esxH, and combined 
esxG and esxH were electroporated into electro-competent Mycobacterium smegmatis 
mc2155 cells.  
 
An aliquot of 200 µl electro-competent M. smegmatis cells was used for one electroporation 
reaction. Electroporation was carried out at 2.5 kV with 1000 ohms resistance. The time 
constant was usually between 15 s and 18 s. After electroporation, 1 ml 7H9 broth was added 
and the cells were incubated at 37°C for 3 hours before a 100 µl aliquot was plated onto 7H11 
agar plates. The 7H11 agar medium was prepared by mixing 19g of 7H11 powder (Becton 
Dickinson, USA) with 970 ml H2O; glycerol, glucose and Tween 80 were added in the same 
way as 7H9 broth. Kanamycin (30 ng/µl) or hygromycin (50 ng/µl) were also added for 
positive transformants selection. The plates were incubated at 37°C for at least 60 hours. 
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Since both p19Kpro and pDMN1 mycobacterial expression vectors were non-inducible 
vectors, the His-tagged fusion proteins were extracted directly from a volume of 100 ml M. 
smegmatis transformants culture which was grown and collected by centrifugation at 4000 xg 
at 4°C. After centrifugation, the supernatant was discarded and the fusion proteins were 
extracted using the MagneHisTM Protein Purification System according to the manufacturer’s 
instructions. However, instead of chemical lysis of the culture as instructed on the manual of 
the MagneHisTM Protein Purification System, ribolysis was applied because it is more 
efficient for breaking open the cell walls of M. smegmatis. The protocol for ribolysis was as 
follows. The pellet (collected from 100 ml M. smegmatis culture) was resuspended in 1 ml 
ice cold PBS (phosphate-buffered saline) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.76 mM KH2PO4, pH 7.4). The resuspension was divided and transferred into two 2 ml 
screw cap microtubes (Quality Scientific Plastics, USA) and an equal volume of 0.1 mm 
glass beads (Roth, Germany) was added to the screw cap microtubes. Another 500 µl PBS 
was added and the mixture was ribolyzed using the ribolyser (Hybaid, UK) with the 
programme set for 6 repeats of 20 sec (ribolysation step) and a subsequent 60 sec at 4°C 
(incubation step). The microtubes were centrifuged at 14000 rpm at 4°C for 10 min and the 
supernatants were pooled and subjected to the His-tagged fusion protein purification 
procedure using the MagneHisTM Protein Purification System. The extracted protein samples 
were analyzed by SDS-PAGE and Western blotting. 
 
2.5.3. SDS-PAGE, Gel Staining and Western blotting 
 
2.5.3.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
SDS-PAGE gels were composed of two parts: a 15% resolving gel and a 3% stacking gel. 
The 15% resolving gel was prepared first, from a master mix containing 2.35 ml H2O, 5 ml 
acrylamide/bisacrylamide 29:1 solution (Bio-rad, USA), 2.5 ml 1.5 M Tris-HCl (Merck, 
Germany) pH 8.8, 0.1 ml 10% SDS (Merck, Germany), 10 µl TEMED (Sigma, Germany) 
and 50 µl 10% ammonium persulphate (Sigma, Germany). After the resolving gel was set, a 3% 
stacking gel was loaded onto the resolving gel. It was prepared from a master mix consisting 
of 7.4 ml H2O, 650 µl acrylamide/bisacrylamide 29:1 solution, 1.25 ml 1.5 M Tris-HCl pH 
6.8, 0.1 ml 10% SDS, 10 µl TEMED and 50 µl 10% ammonium persulphate. After the 
stacking gel was set, the tank was filled up with SDS-PAGE running buffer (25 mM Tris, 192 
mM glycine, 0.1% SDS). 
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Prior to sample loading, 10 µl protein sample was mixed with 10 µl sample buffer which was 
prepared as a master mix containing 3.4 ml 1M Tris, pH 6.8, 2 ml glycerol, 3 ml 20% SDS, 
0.5 ml 0.75% bromophenol blue and 1 ml β-mercaptoethanol. The 20 µl protein sample mix 
was heated at 100°C for 5 min. The protein samples and protein pre-stained marker 
(Fermentas, USA) were loaded parallel in the same gel. The gel was run at 150 Volts until the 
dye front reached the bottom of the gel. 
 
2.5.3.2 Polyacrylamide Gel Staining Technique 
 
Two staining techniques were used to visualize the proteins in the polyacrylamide gel, 
namely Coomassie blue staining and silver staining.  
 
Two versions of the Coomassie blue staining methods were used in this project. The standard 
version was applied to stain mini-SDS-PAGE gels; while the modified version (which is 
suitable for mass spectrometric analysis of the protein spots) was applied to 2D-SDS-PAGE 
gels. With the standard Coomassie blue staining technique, the post-run polyacrylamide gel 
was immersed in Coomassie staining solution [0.25% brilliant blue R250 powder (Sigma, 
Germany), 45% methanol, 10% glacial acetic acid] and shaken on a rotator for 2 hours. The 
gel was destained with destaining solution (45% methanol, 10% glacial acetic acid) for three 
hours and then stored in water. With the modified Coomassie blue staining technique, the 2-D 
SDS-PAGE gel was firstly immersed in 250 ml Coomassie 1 solution [0.025% (w/v) Brilliant 
blue R-250, 25% (v/v) isopropanol, and 10% (v/v) acetic acid] and heated in a microwave for 
2 min. It was placed on a shaker for fixation overnight. The solution was decanted and the gel 
was immersed in 250 ml Coomassie II solution [0.003% (w/v) Brilliant Blue R-250, 10% (v/v) 
isopropanol, 10% (v/v) acetic acid] and heated in a microwave for 2 min. It was placed on a 
shaker for 30 min. The solution was decanted and the gel was immersed in 250 ml Coomassie 
III solution [0.003% (w/v) Brilliant blue R-250, 10% (v/v) acetic acid] and heated in a 
microwave for 2 min. Thereafter, it was placed on a shaker for 30 min. The solution was 
decanted again and the gel was immersed finally in 250 ml destaining solution [10% (v/v) 
acetic acid, 1% (v/v) glycerol] overnight. The gel was stored in distilled water after 
destaining. 
 
With the silver staining technique, the post-run polyacrylamide gel was soaked in fixation 
solution [50% (v/v) ethanol, 12% (v/v) glacial acetic acid, 0.05% (v/v) formalin] at room 
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temperature for at least 2 hours. The fixation solution was discarded and the gel was 
immersed in washing solution [20% (v/v) ethanol] for 20 min. The washing solution was 
changed twice during the 20 min. The washing solution was discarded and sensitizing 
solution [0.02% (w/v) sodium thiosulfate] was added. The gel was soaked in sensitizing 
solution for 2 min and washed twice with cold deionized water twice, each for 1 min. The gel 
was subsequently soaked in fresh cold silver staining solution [0.2% (w/v) silver nitrate, 
0.076% (v/v) formalin] at 4°C for 1 hour with constant shaking. After the staining, the gel 
was rinsed twice with H2O, 1 min each. The development was done by immersing the gel in 
developing solution [6% (w/v) Na2CO3, 0.0004% (w/v) Na2S2O3, 0.05% (v/v) formalin] until 
the light brown coloured bands showed up on the gel. The developing reaction was stopped 
by adding 50 ml termination solution [12% (v/v) glacial acetic acid]. The gel was stored in 1% 
(v/v) acetic acid solution. 
 
2.5.3.3 Western blotting 
 
Post-run polyacrylamide gels were also used for Western blotting for detecting His-tagged 
fusion proteins. As soon as the electrophoresis was completed, the Western blotting apparatus 
was set up in the following order: 1 pad, 1 Whatman sheet, polyacrylamide gel, HybondTM-
ECL nitrocellulose membrane (GE Healthcare, USA), 1 Whatman sheet, and 1 pad. The 
sandwich was closed and inserted into a Western blotting apparatus (Bio-rad, USA), together 
with an ice pack. The buffer chamber was filled with Transfer buffer (25 mM Tris, 192 mM 
glycine, 20% methanol, pH 8.3), a magnetic bar was placed inside the chamber and the whole 
apparatus was placed onto a magnetic stirrer. The transfer was done at 100 volts for 60 min at 
4°C. The apparatus was dismantled and the membrane was taken out and reversibly stained 
with Ponceau red dye for verification of protein transfer. The membrane was blocked 
overnight with blocking buffer (20 mM Tris, 137 mM NaCl, 0.1% Tween 80, 10% milk 
powder, 1% BSA) at room temperature. The blocked membrane was rinsed three times with 
TBS-T buffer (20 mM Tris, 137 mM NaCl, 0.1% Tween 80), and incubated with mouse anti-
6x histidine primary antibody (Invitrogen, USA), previously diluted in TBS-T buffer at 
1:5000, for 60 min at room temperature. The membrane was rinsed twice with TBS-T buffer 
and then washed 3 times, each for 10 min, in TBS-T buffer with shaking. Horse-radish 
peroxidase (HRP)-conjugated goat anti-mouse secondary antibody (Santa-cruz, USA), was 
applied to the membrane with in a 1:1000 dilution in TBS-T buffer. The membrane was 
incubated for 60 min at room temperature. The washing step was repeated as described 
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previously, and the signal was developed using ECL detection fluid (GE healthcare, USA). 
The membrane and an autoradiographic film were placed into an autoradiography cassette 
(GE healthcare, USA) for between 10 sec and 1 hour. The film was developed using a Hyper 
Processor developer (Amersham, USA). 
 
An alternative Western blotting technique was also performed using the HisDetectorTM 
Western Blot Kit (KPL, USA) in cases where antibody detection through ECL were 
problematic. Additionally, anti-mycosin-3 antibody (a kind gift from N.C. Gey van Pittius) 
was used for detecting the His-tagged fusion mycosin-3. 
 
2.5.4. Large-scale protein expression and purification 
 
The optimal expression conditions obtained in the test expression were applied when large-
scale protein purification was required. For large-scale His-tagged fusion protein purification, 
large cultures (1-4 liter) of transformed E. coli or M. smegmatis was prepared for expression 
according to the specific expression vector used. After the expression was completed, the 
cells were collected by centrifugation at 4000 xg at 4°C. The supernatant was discarded and 
the pellets were stored at -80°C. The frozen pellets were prepared and run over the Ni-NTA 
Superflow Columns (Qiagen, Germany) according to the manufacturer’s instructions, for 
purification of the His-tagged proteins. The end products, purified His-tagged fusion proteins, 
were stored at -20°C if it was not for immediate use. 
 
2.5.5 Protein Assays 
 
Protein was quantified using the Quick StartTM Bradford Protein Assay Kit (Bio-rad, USA). 
An aliquot of 10 µl protein sample (or the protein standards) was mixed with 200 µl of the 
Quick StartTM Bradford dye reagent in one well on a 96-well microtiter plate. The plate was 
incubated at room temperature for 5 min. The absorbance was measured at a wavelength of 
595 nm using 96-well plate reader (BioTek, USA). Protein standards were prepared by 
dissolving bovine serum albumin (BSA) powder in distilled water making up the solutions 
with concentrations of 2 mg/ml, 1.5 mg/ml, 1 mg/ml, 0.75 mg/ml, 0.5 mg/ml and 0.25 mg/ml. 
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2.6. Protease assay, 2-Dimensional gel electrophoresis and mass spectrometric analysis 
 
2.6.1 Protease Assay 
 
The protease assay method used was published by Yamini, et al. (2010). The buffer 
conditions of the His-tagged fusion proteins in the eluant of the large-scale protein 
purification were changed using a PD-10 desalting column (GE health science, USA). In 
order for the proteins to be optimally visualized on 2-D gel with Coomassie blue staining, the 
proteins were concentrated using centrifugal filter devices (Millipore, USA). MycP3 activity 
assays were performed in a mycosin activity buffer (20 mM Tris pH 8, 100 mM NaCl, 2 mM 
CaCl2, and 0.01% Brij-35) (Ohol et al., 2010), together with its potential substrates (molar 
ratio was 1:1). The reaction was incubated at 37°C for 60 min to allow protease cleavage to 
take place. 
 
2.6.2 Two-Dimensional Gel Electrophoresis and Mass Spectrometric Analysis 
 
Prior to isoelectric focusing (IEF) (first dimension gel electrophoresis), protein samples had 
to undergo a clean-up procedure using the ReadyPrepTM 2-D Cleanup Kit (Bio-Rad, USA) in 
order to remove any salts in the protein sample which might interfere with the conductivity of 
the IEF run. For mass spectrometric analysis, the amount of protein loaded onto the IEF strip 
was around 200 µg to be visualized by Coomassie blue stain. For silver staining, 60 µg of 
protein was sufficient. 
 
One hundred microliters of cleaned-up protein sample was mixed with 100 µl rehydration 
buffer (Bio-Rad, USA). The 200 µl mixture was transferred onto one lane of the tray. The 
mixture was covered by one ReadyStrip IPG strip, pH 4-7 (Bio-Rad, USA); and incubated at 
room temperature for one hour. Four milliliters of mineral oil was added on top of the strip 
allowing dehydration overnight. The strip was transferred into one lane of the IEF chamber, 
and the lane was filled with 3 ml mineral oil. The run was set at 8000 volts for 40000 voltage 
hours (Protean IEF cell, Bio-Rad, USA). After the run, the strip was stored at -80°C until 
being used for the second dimension polyacrylamide gel electrophoresis. 
 
Prior to the second dimension SDS-PAGE, the strip was treated by immersing into two 
equilibration buffers and shaken for 10 min at room temperature, 10 ml for each, sequentially. 
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The first buffer contained 0.375 M Tris-HCl, pH 8.8, 6 M urea, 20% glycerol, 2% SDS, and 2% 
DTT (Bio-Rad, USA). In the second buffer, instead of 2% DTT, 2% iodoacetamide was used. 
 
The 15% acrylamide gel was prepared from a master mix made from 60.16 ml 1.5 M Tris-
HCl, pH 8.8, 120 ml acrylamide/PDA [30% acrylamide and 0.8% PDA, deionised with 
mixed resin TMD-8 (Sigma, Germany) and then filtered out], 56.9 ml H2O, 0.92 ml 20% 
sodium thiosulphate, 123 µl TEMED and 1.85 ml 10% APS. The gel was overlaid with water 
saturated butanol. After the gel was set, the wells were washed with water and dried by 
blotting with Whatman paper. 
 
The strip, together with a small piece of whatman paper (1cm length and the same width as 
the strip) which was wet with 8 µl pre-stained protein ladder solution (Fermentas, USA), was 
loaded onto the gel. One milliliter molten 0.5 % agarose (Bio-Rad, USA) was overlaid onto 
the top of the strip. After the agarose was set, the apparatus was set up. The top section was 
filled with cathode buffer [192 M glycine pH 8.3 (adjusted with Tris), 0.1% SDS]; and the 
tank was filled with a mixture of 1.5 L anode buffer [0.375 M Tris, pH 8.8 (adjusted with 
glacial acetic acid)] and 1.5 L distilled water. The electrophoresis was carried out at 180 volts 
at 12°C for 6 hours or until the bromophenol blue dye front reached the bottom. 
 
The 2-D polyacrylamide gel was stained with Coomassie blue or silver nitrate (See Section 
2.5.3.2 for details). Gels containing only mycosin-3 or the individual potential substrates 
acted as the control gels, while gels with protease activity assay products acted as the result 
group. These two groups were compared in order to identify spots of difference. Identified 
spots would be cut out and sent for mass spectrometric analysis for protein sequencing and 
identification (Mass Spectrometry Service, Department of Biotechnology, University of 
Western Cape). 
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Chapter 3 Results 
 
3.1 Cloning of mycP3 and potential substrates 
 
Three groups of primers were successfully designed in this study. In Group 1, 8 pairs of 
primers were designed for amplifying genes of mycosin-3 with transmembrane region, 
mycosin-3 without transmembrane region, PE5, PPE4, combined PE5 and PPE4, esxG, esxH, 
and combined esxG and esxH, for cloning into Escherichia coli expression vector pET-28a. 
In Group 2, 7 pairs of primers were designed for amplifying genes of mycosin-3 without 
transmembrane region, PE5, PPE4, combined PE5 and PPE4, esxG, esxH, and combined 
esxG and esxH, for cloning into Mycobacterium smegmatis expression vector p19Kpro. In 
Group 3, the same strategy was applied as in Group 2; but they were designed for cloning 
into the other Mycobacterium smegmatis expression vector pDMN1. 
 
All primers mentioned above were successfully used to generate the correct amplification 
products through PCR. PCR products were all successfully cloned into the pGEM-T Easy 
cloning vector and subsequently subcloned into the respective expression vectors. Colony 
PCR and sequencing of the constructs confirmed all cloning steps and verified that all 22 
clones were generated successfully. Owing to the large amount of experimental results for 
this cloning section, only the confirmatory colony PCR results for the recombinant pET-28a 
expression vectors are given in this section (see Figure 3.1). The sizes of the PCR fragments 
of each gene for cloning into the expression vectors p19Kpro and pDMN1 were basically the 
same as those for cloning into pET-28a, so colony PCR results for these two mycobacterial 
expression vectors are not given in this chapter. Detailed results are shown in Addendum 6.2.  
 
Verification of these clones was also done by plasmid DNA sequencing (results not shown). 
All clones contained the insert of interest with no mutations detected by sequencing. 
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Figure 3.1 Agarose gel electrophoresis image of colony PCR confirmation of recombinant expression vector 
pET-28a containing inserts of interest, Lane 1: 1kb GeneRuler® DNA markers (Fermentas, USA); Lane 2: esxG 
(296 bp); Lane 3: esxH (293 bp); Lane 4: combined esxG and esxH (619 bp); Lane 5: PE5 (311 bp); Lane 6: 
PPE4 (1544 bp); Lane 7: combined PE5 and PPE4 (1855 bp); Lane 8: mycosin-3 without hydrophobic tail 
(1058 bp) and Lane 9: mycosin-3 with hydrophobic tail (1241 bp) 
 
 
3.2 Expression and Purification 
 
Test expression of the pET-28a expression vector recombinant clones were initially 
conducted by running crude cell lysate of a 1 ml sample, which was taken from the 
expression culture in each hour interval after induction using IPTG, on SDS-PAGE. The 
over-expressed protein was supposed to show as a band with increasing intensity over time 
compared to the background. However, such a pattern was not identifiable on the 
polyacrylamide gels (an example is shown in Figure 6.20 in the Addendum). 
 
In order to increase the visibility of the expressed proteins, Western blotting was conducted 
using the anti-6x Histidine primary antibodies. For unclear reasons, the Western blotting 
failed to visualize the bands of interest after autoradiography. A test experiment was done to 
investigate this problem. Cell lysate and primary antibody were applied separately as two 
spots on the same piece of nitrocellulose membrane. The Western blot and detection were 
conducted on the two spots in parallel and the results showed that the spot of primary 
antibody expressed a very strong signal while the spot of cell lysate gave no signal (results 
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not shown). It was thus unclear why expression was undetectable, but it is assumed that 
expression levels were too low to detect in a crude sample. 
 
To address this problem, the strategy was changed and we decided to purify His-tagged 
fusion protein in order to concentrate it for SDS-PAGE, so that there were sufficient amounts 
of expressed fusion proteins to be seen on the gel and the background could be largely 
reduced. Interestingly, the His-tagged esxG, and His-tagged esxH could not be stained visibly 
by Coomassie Blue R 250 (results not shown). However, they could be visualized by silver 
staining. The expression levels of the mycosins (with or without transmembrane region), 
PPE4, and combined PE5 and PPE4 were so low that they could not even be visualized by 
silver staining. However, using previously-generated anti-mycosin-3 antibodies the presence 
of the expressed mycosins was confirmed by Western blotting. Expressed and purified fusion 
proteins, PE5 and combined esxG and esxH, could be stained by both staining methods.  
 
Test expressions were done under 9 different expression conditions (as indicated in Chapter 2, 
Materials and Methods), and the optimal condition (0.5 mM IPTG, 30°C) results are shown 
in Figure 3.2. Only the silver stained polyacrylamide gels are shown. In these gels, the 
proteins PE5, esxG, esxH and the combined esxG and esxH can be clearly seen as thick 
bands. However, the bands for mycosin-3 without transmembrane region, mycosin-3 with 
transmembrane region, PPE4, and the combined PE5 and PPE4 cannot be identified because 
of the background and their low expression levels. 
 
The His-tag protein purification kit was not able to separate the His-tagged protein from all 
the background proteins, resulting in multiple bands appearing on the gel. In order to identify 
the correct bands, Western blotting using the HisDetectorTM Western Blot Kit was applied. 
The results are shown in Figure 3.3. 
 
The Western blot kit also detected some background proteins. However, the proteins of 
interest could be identified by their sizes and relative abundance. 
 
Anti-mycosin-3 antibodies were used for the detection of the purified His-tagged mycosin-3 
fusion proteins when neither the Coomassie blue or silver staining methods nor the 
Colourimetric Western Blot kit were able to detect the proteins due to the extremely low 
expression levels. The anti-mycosin-3 antibody Western blotting results are shown in Figure 
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3.4. Both purified His-tagged mycosin-3 with transmembrane region and His-tagged 
mycosin-3 without transmembrane region were able to be detected by Western blotting using 
anti-mycosin-3 antibodies in the pellet, flow through (when column binding capacity is 
reached) and the eluant. 
(a) 
(b) 
 
Figure 3.2 Silver-stained SDS-PAGE imageof purified expressed recombinant M. tuberculosis proteins, (a) Lane 
1: PageRuler® prestained protein ladder (Fermentas, USA); Lane 2: cell lysate; Lane 3: purified His-tagged 
mycosin-3 without the transmembrane region (~36.2 kDa); Lane 4: purified His-tagged mycosin-3 with the 
transmembrane region (~42.2 kDa); Lane 5: purified His-tagged PE5 (~10.6 kDa); Lane 6: purified His-tagged 
PPE4 (~52.8 kDa); Lane 7: purified His-tagged combined PE5 and PPE4; Lane 8: His-tagged protein marker 
(Invitrogen, USA); (b) Lane 1: PageRuler® prestained protein ladder (Fermentas, USA); Lane 2: cell lysate; 
Lane 3: empty lane; Lane 4: purified His-tagged esxG (~10.7 kDa); Lane 5: purified His-tagged esxH (~11.3 
kDa); Lane 6: purified His-tagged esxG and esxH; Lane 7: His-tagged protein marker (Invitrogen, USA). 
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(a) 
(b) 
 
Figure 3.3 Western blots of SDS-PAGE gels in Figure 3.2. Bands indicated with arrows show the target His-
tagged fusion proteins. (a) Lane 1: PageRuler® prestained protein ladder (Fermentas, USA); Lane 2: cell lysate; 
Lane 3: purified His-tagged mycosin-3 without the transmembrane region (~36.2 kDa); Lane 4: purified His-
tagged mycosin-3 with the transmembrane region (~42.2 kDa); Lane 5: purified His-tagged PE5 (~10.6 kDa); 
Lane 6: purified His-tagged PPE4 (~52.8 kDa); Lane 7: purified His-tagged combined PE5 and PPE4; Lane 8: 
His-tagged protein marker; (b) Lane 1: PageRuler® prestained protein ladder (Fermentas, USA); Lane 2: cell 
lysate; Lane 3: empty lane; Lane 4: purified His-tagged esxG (~10.7 kDa); Lane 5: purified His-tagged esxH 
(~11.3 kDa); Lane 6: purified His-tagged esxG and esxH; Lane 7: His-tagged protein marker. 
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(a) 
(b) 
 
Figure 3.4. Western blots of Ni-NTA superflow column-purified His-tagged mycosin-3 with or without the 
transmembrane region fusion proteins using rabbit anti-mycosin-3 antibody. (a) Lane 1: Pellet from cell lysate 
of pET-28a-mycosin-3 recombinant plasmid DNA transformants; Lane 2: Flow through of cell lysate of 
transformants expressing mycosin-3 without transmembrane region; Lane 3: The eluant of mycosin-3 without 
the transmembrane region using MagneHis Purification System; Lane 4: The eluant of mycosin-3 without 
transmembrane region using Ni-NTA superflow column; Lane 5: Flow through of cell lysate of transformants 
expressing mycosin-3 with the transmembrane region; Lane 6: The eluant of mycosin-3 with the transmembrane 
region using MagneHis Purification System; Lane 7: The eluant of mycosin-3 with transmembrane region using 
Ni-NTA superflow column; Lane 8: GST-tagged mycosin-3 fusion protein as a positive control. (b) Lane 1: 
flow through of cell lysate of 2 liters of transformants expressing mycosin-3 without the transmembrane region; 
Lane 2: highly concentrated eluant (from 6 liters of E. coli culture) of mycosin-3 without the transmembrane 
region; Lane 3: flow through of cell lysate of transformants expressing the combined esxG and esxH; Lane 4: 
eluant of the His-tagged combined esxG and esxH fusion proteins. 
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The test expression of the p19Kpro mycobacterial expression vector was done by purifying 
His-tagged fusion protein from a small volume of mycobacterial culture and running it on 
SDS-PAGE with silver staining. For unknown reasons, none of the 7 different His-tagged 
fusion proteins could be isolated in high enough amounts to be visualized by silver staining 
(results not shown). 
 
The test expression of the pDMN1 mycobacterial expression vector was done in the same 
manner as p19Kpro. Unlike the normal consistent growth of M. smegmatis for all 7 of the 
clones containing the p19Kpro recombinant expression vectors, the growth of M. smegmatis 
for 7 of the clones containing the pDMN1 recombinant expression vectors varied on both the 
plate and the broth. On 7H11 agar plates, M. smegmatis with pDMN1-esxG, pDMN1-esxH, 
pDMN1-esxG/esxH, pDMN1-PE5, and pDMN1-PE5/PPE4 showed equally good growth; but 
M. smegmatis with pDMN1-mycP3 grew much slower. Very interestingly, the survival of M. 
smegmatis with pDMN1-PPE4 was very low on solid media compared to the other 
transformants (Figure 3.5). The bacteria with pDMN1-PPE4 that did survive grew very 
slowly on both 7H11 agar and in 7H9 broth. In 7H9 broth, the growth of M. smegmatis with 
different pDMN1 transformants also varied in each culturing attempt. The M. smegmatis 
culture with the pDMN1-PPE4 construct also tended to form aggregates at the start of the 
culture. It took around 6 days for these cultures to grow to an OD600nm of 0.6. The others had 
differential growth, growing well at one time, but very slowly at another. Sometimes, the 
culture even died (such as one culture of the pDMN1-esxH transformant). Apart from the 
differences in growth rate, no His-tagged fusion proteins could also be purified from most of 
these recombinants (results are shown in Addendum, Figure 6.29 and 6.30). However, the co-
expression and co-purification of His-tagged esxG and esxH was successful (Figure 3.6). 
 
 
Figure 3.5 Comparison of the growth of M. smegmatis pDMN1-PPE4 (1), pDMN1-PE5/PPE4 (2), pDMN1-PE5 
(3) and pDMN1-mycP3 (4) transformants on 7H11 agar plates after 72 hours of incubation at 37°C 
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Figure 3.6 Image of silver-stained SDS-PAGE gel. Lane 1: PageRuler® prestained protein ladder (Fermentas, 
USA); Lane 2: His-tagged esxG isolated from M. smegmatis pDMN1 recombinant clone; Lane 3: His-tagged 
esxH isolated from pDMN1 recombinant clone; Lane 4: the combined esxG and esxH isolated from pDMN1 
recombinant clone (esxH was His-tagged) 
 
3.3 Protein quantification, Protease Assay, 2-D PAGE and Mass Spectrometric Analysis 
 
Since mycobacterial expression vectors p19Kpro and pDMN1 were not able to express any of 
the target fusion proteins except for the combined esxG and esxH, only E. coli expressed 
fusion proteins were used for this part of the project. However, according to the test 
expression results, esxG and esxH individually could not be expressed in significant amount 
using the MagneHisTM Protein Purification System, and they showed little yield using Ni-
NTA Superflow columns; while the expression of combined PE5 and PPE4 was not 
detectable at all. Therefore, single esxG, single esxH, and the combined PE5 and PPE4 could 
not be used in this part of the study either. 
 
The concentrations of the freshly prepared His-tagged mycosin-3 without transmembrane 
region, His-tagged mycosin-3 with transmembrane region, His-tagged PE5, His-tagged PPE4, 
and His-tagged combined esxG and esxH are given in the Addendum (Table 6.1). The five 
different fusion proteins were run individually on 2-D SDS-PAGE to act as the control group. 
All 5 gels in the control group were silver-stained. The gels loaded with mycosin-3 were used 
for Western blotting as well. These Western blots also belong to the control group. The 
control group is shown in Addendum 6.4. The experimental group contained the silver-
stained 2-D SDS-PAGE gels of protein products from the protease assays (mycosin-3 
with/without transmembrane region + PE5, mycosin-3 with/without transmembrane region + 
PPE4, mycosin-3 with/without transmembrane region + the combined esxG and esxH). The 
gels in the experimental group are shown in Figure 3.7, Figure 3.8 and Figure 3.9. 
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(a) 
(b) 
 
Figure 3.7 2-D SDS-PAGE results of the experimental group using His-tagged PE5 fusion protein as the 
substrate (the arrows indicate the spots of fusion target proteins). (a) Mycosin-3 without the transmembrane 
region + PE5; (b) Mycosin-3 with the transmembrane region + PE5. 
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(a) 
(b) 
 
Figure 3.8 2-D SDS-PAGE results of the experimental group using His-tagged PPE4 fusion protein as the 
substrate (the arrows indicate the spots of fusion target proteins). (a) Mycosin-3 without the transmembrane 
region + PPE4; (b) Mycosin-3 with the transmembrane region + PPE4;  
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(a) 
(b) 
 
Figure 3.9 2-D SDS-PAGE results of the experimental group using His-tagged combined esxG and esxH fusion 
protein as the substrate (the arrows indicate the spots of fusion target proteins). (a) Mycosin-3 without the 
transmembrane region + combined esxG and esxH; (b) Mycosin-3 with the transmembrane region + combined 
esxG and esxH. Blue arrows indicate common spots among the two gels while red arrows indicate the two spots 
only appearring in one 2-D experiment but not the other. 
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Because of the large amount of background on the gel, spots representing the target fusion 
proteins were not easily identifiable. By comparing the spot patterns between the control gels 
and the experimental gels, as well as considering the size of the fusion proteins, the spots for 
the target fusion proteins were identified (Figure 3.7 – 3.9). However, the positions of those 
spots on the experimental gels did not deviate from the corresponding spots on the control 
gels (i.e. the positions of the spots did not deviate after the treatment of the putative purified 
substrates PE5, PPE4, combined esxG and esxH with mycosin-3). 
 
Due to the absence of any identifiable variation between the protease assay gels and the 
control gels, we were unable to perform gel spot protein sequencing using Mass Spectrometry. 
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Chapter 4 Discussion 
 
The genes encoding mycosin-3 with/without transmembrane region, PE5, PPE4, combined 
PE5 and PPE4, esxG, esxH, and combined esxG and esxH were cloned from the 
Mycobacterium tuberculosis H37Rv reference strain into both E. coli and mycobacterial 
expression vectors. The cloning was successful but the expression and purification were 
troublesome. The His-tagged target fusion proteins were not detectable in a 1 ml aliquot of 
the E. coli culture collected at each hour interval after the initiation of the expression (with 
addition of IPTG), using either Coomassie blue stain or silver stain on SDS-PAGE gels 
(Figure 6.20). Western blotting was supposed to amplify the 6x His tag signal by at least a 
thousand times. However, the Western detection using anti-His-tag (C-terminal) primary 
antibody failed. A test experiment was conducted as described in Section 3.2. The positive 
result from the spot of primary antibody implies that the binding between the primary 
antibody and the secondary HRP-conjugated anti-mouse antibody was successful and that the 
detection kit worked as well. The spot of test expression culture lysate showed a negative 
result. Apparently in this case, the binding between the target His-tagged fusion protein and 
the commercial anti-His-tag (C-terminal) primary antibody did not occur. It might be due to 
the following reasons: 1. the C-terminal 6x His-tag was prevented from binding to the anti-
His antibody even though the protein sample was pre-treated with SDS-PAGE sample buffer 
before running SDS-PAGE and Western blotting (implying that the folding of the target 
protein by E. coli did not favour such a detection method); 2. the expression level in the 1 ml 
aliquot of the expression culture was so low that even Western blotting was not able to detect 
the target protein; or 3. the quality of the purchased primary anti-His antibody was not good. 
 
In order to overcome the difficulties in the detection of the target His-tagged fusion protein 
expression, the expression and detection protocols were altered bearing in mind the three 
possible problems mentioned above. Purification of the His-tagged fusion proteins under 
denaturing conditions might have sorted out the problem regarding the hindrance of the 
binding site and thereby increase the yield of soluble proteins. However, this method does not 
favour the downstream experiments where the target proteins were required to be in their 
native form and active so that functional studies could be performed. Re-folding of denatured 
proteins is frequently unsuccessful and troublesome. Each protein may have its own unique 
folding mechanism. Therefore it was considered not worthwhile to try to generate denatured 
target proteins and refold them. We decided that an attempt to get more concentrated target 
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fusion protein for the detection was a better option. The alternative strategy was thus to 
perform small-scale His-tagged fusion protein purification before the detection using the 
staining methods and Western blotting. 
 
This alternative strategy seemed to work well (Figure 3.2 and 3.3; Figure 6.21 – 6.28). 
However, the expression levels remained very low, even though the His-tagged fusion protein 
was purified and the background was largely reduced (compare to Figure 6.20). The 
expression levels for His-tagged mycosin-3 with/without transmembrane region, His-tagged 
PPE4 and the combined PE5 and PPE4 were exceedingly low (not identifiable with either 
Coomassie blue stain or Silver stain). The small secreted proteins, His-tagged PE5, His-
tagged esxG, His-tagged esxH, and His-tagged combined esxG and esxH, could be detected 
by silver stain, and also by Coomassie blue stain if a larger culture was used for protein 
extraction or the purified protein was concentrated. It implies that E. coli is not capable of 
expressing large M. tuberculosis proteins such as mycosin-3, PPE4 and combined PE5 and 
PPE4 in significant amounts (Daugelat et al., 2003). The possible reasons for this will be 
discussed later in this chapter. However, small secreted proteins (~10 kDa) PE5, esxG, esxH 
and even the combined esxG and esxH (20 kDa) were much easier for E. coli to express. Our 
study confirmed that silver stain is a more sensitive stain than Coomassie blue stain. 
Coomassie brilliant blue G-250 dye is able to bind to Phe and Tyr due to hydrophobic 
interaction, and Lys, His and Arg in a lesser extent due to electrostatic interaction (Georgiou 
et al., 2008). Upon protein binding, the protein-dye complex shifts its absorption peak to 615 
nm to 625 nm compared to the original absorption peak of the dye (450 nm). In the other 
hand, silver nitrate molecules bind and form complexes with the proteins by interacting with 
sulfhydryl (Met and Cys) and carboxyl groups (Asp, Glu and C-terminus of the protein) 
(Rabilloud, 1990). The silver ions are reduced to silver metal in slight alkaline conditions 
(formaldehyde in sodium or potassium carbonate solution). The reduction rate will increase 
when there is some silver metal available giving a better stained image. Silver stain increases 
the sensitivity from µg to ng compared to Coomassie blue stain (Rabilloud, 1990). It explains 
the reason why esxG and esxH individually could be stained by silver nitrate but not by 
Coomassie blue when a small culture was used (~10 ml) (results not shown). 
 
For the small-scale His-tagged fusion protein purification, the MagneHisTM Protein 
Purification System was used. This kit uses a batch procedure for the purification where the 
affinity matrix resin is incubated in the cell lysate solution before the wash and the elution. 
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For some reason, this batch purification method was able to generate a better purification 
profile than the column purification method (Ni-NTA Superflow columns) (See Figure 3.4 
for the comparison). Moreover, it was found that individually expressed esxG and esxH could 
not be purified by the column method (only when they were co-expressed) but the batch 
method could purify all three (results not shown). This might be due to the binding 
mechanism of the fusion proteins and the immobilized nickel ions on the matrix resins. It 
suggests that the free beads onto which the nickel ions were immobilized have a better 
chance for the His-tagged fusion proteins to access than the stationary matrix in the column. 
In other words, in this case, the bead purification method was more efficient than the column 
purification method. It was also found that the expression of esxG and esxH were dependent 
on each other. Although they could be expressed alone, this was at a very low level. However, 
the expression levels were much higher when they were co-expressed. It is interesting to note 
that the genes encoding esxG and esxH belong to a single operon and that they are co-
operonically regulated. The proteins also interact with each other after being produced 
(Figure 6.36). The same phenomenon was observed with the expression of PE25 protein 
(Rv2431c) and PPE41 protein (Rv2430c) where the genes encoding for these two proteins are 
also organized in an operon and they also form a complex (Tundup et al., 2006). Since the 
MagneHisTM protein purification system is only suitable for small-scale protein purification, 
it is very labour-intensive if it is used for large-scale His-tagged fusion protein purification. 
Therefore Ni-NTA Superflow columns were used for the large-scale fusion protein 
purification in spite of the lower purification efficiency compared to the MagneHisTM protein 
purification system. 
 
Apart from the problem of low expression discussed above, there were two other major 
problems associated with the expression and purification of the His-tagged fusion proteins. 
These were associated with the rare codons in the M. tuberculosis genome and the poor purity 
of the purified His-tagged fusion proteins. These two problems resulted in unavoidable large 
amounts of background proteins, insoluble proteins forming inclusion bodies, and truncated 
proteins after purification. They made the identification of the target fusion proteins on 2-D 
gels very difficult. The target fusion proteins were also potentially vulnerable due to the 
presence of E. coli proteases. No protease inhibitors could be used in the purification as it 
could potentially inhibit the activity of mycosin-3. 
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M. tuberculosis, like all other species in the genus Mycobacterium, has a high GC content 
(65.6%), unique codon preferences and proteins which tend to be rich in glycine, alanine, 
proline and arginine. All these factors can cause problems for overexpression of 
mycobacterial proteins in E. coli. Numerous studies have shown that E. coli struggles to 
express mycobacterial proteins (e. g. Daugelat et al., 2003). In this project, E. coli was able to 
express the small secreted proteins (soluble in their native form), PE5, esxG and esxH. It 
struggled to express larger proteins, especially the ones with hydrophobic regions such as 
PPE4 and mycosin-3 with/without the transmembrane region. When the target gene was too 
long, such as the gene for the combined PE5 and PPE4, the expression was almost abolished 
(no detection whatsoever). Mycobacteria have specific codon preferences which are different 
from E. coli. When mycobacterial genes are being expressed in E. coli, there are low 
concentrations of respective tRNAs in the cell (Lkemura, 1981). Depletion of those specific 
tRNAs during protein synthesis results in a slow translation rate (Varenne et al., 1984). The 
translation might stop if there is no tRNA with the rare codon coming into the protein 
synthesis machinery. This leads to the formation of incomplete target fusion proteins. The 
full length target fusion proteins might also get cleaved at their N- or C-termini by proteases 
in the cell. These factors result in the production of truncated products of the original proteins. 
The truncated product is described as a protein that does not achieve its full length or obtain 
its proper conformation, and thus lack some of the amino acid residues that are present in a 
normal protein. A truncated protein generally cannot perform its normal function because its 
structure is incapable of doing so. Evidence for the production of truncated products of 
mycosin-3 is shown in Figure 6.32 and Figure 6.33 where a number of spots representing not 
only the mycosin-3 but also truncated version of it were picked up by the anti-mycosin-3 
antibodies. However, some of these spots might also be degradation products of mycosin-3. 
 
There are several ways of avoiding truncated products and reducing the production of 
inclusion bodies while doing expressing foreign genes in E.coli. One way is to use E. coli 
strains supplemented with genes encoding for tRNA molecules which are capable of 
recognizing rare codons. These E. coli strains are usually commercially available. However, 
these strains are not made solely for M. tuberculosis gene expression. A better option is to 
synthesize a gene which encodes for the same protein but with all the rare codons used in M. 
tuberculosis changed to the ones which are preferred in E. coli. This codon-optimized gene 
can then be ligated into an expression vector and expressed. However, this is a very costly 
method, especially if large numbers of proteins are needed to be expressed or if protein sizes 
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are large. The third method is to clone and express the M. tuberculosis gene in M. 
tuberculosis itself. Owing to the extremely slow growing behaviour of M. tuberculosis, M. 
smegmatis is usually used as the expression host for this purpose as it is a fast-growing 
mycobacterium. A number of mycobacterial expression vectors have been generated, which 
is able to generate correctly folded and post-translationally modified proteins using M. 
smegmatis as the host (Daugelat et al., 2003). In this project, the third method was applied. 
The results will be discussed later in this chapter. 
 
The second major problem was the poor purity of the purified target His-tagged fusion 
proteins. It is well known that His-tagged fusion protein purification usually generate impure 
co-eluants. Nonspecific binding of untagged proteins is usually the problem. Although 
histidine occurs relatively infrequently, some cellular proteins contain two or more adjacent 
histidine residues. These proteins have an affinity for the IMAC (immobilized metal-affinity 
chromatography) matrix [such as nickel-nitriloacetic acid (Ni+2-NTA)-immobilized resins 
used in this project] and may co-elute with the protein of interest, resulting in significant 
contamination of the final product. In E. coli, proteins observed to co-purify with His-tagged 
target proteins can be divided into four groups: (i) proteins with natural metal-binding motifs, 
(ii) proteins with histidine clusters on their surfaces, (iii) proteins that bind to heterologously 
expressed His-tagged proteins, for example by a chaperone mechanism, and (iv) proteins with 
affinity to agarose-based supports (Bolanos-Garcia and Davies, 2006). Many of these 
impurities are stress-responsive proteins, suggesting that the cultivation conditions and the 
bacterial strain have an influence on their abundance and consequently their appearance as a 
contaminating species in the target protein preparation; it is therefore recommended to induce 
as little stress as possible during cultivation of E. coli cells (e.g. adding 0.1% glucose in the 
culture medium or using shake flasks without baffles) (Block et al., 2009).  
 
Disulfide bond formation between the protein of interest and other proteins can also lead to 
contamination.  Ten mM 2-mercaptoethanol can be used in the loading, wash, and elution 
buffers for eliminating this potential problem (Bornhorst and Falke, 2000). Nonspecific 
hydrophobic interactions can also cause some copurification with the desired protein. 
Including low levels (up to 1%) of the non-ionic detergent Tween 20 or Triton X-100 in the 
protein buffers can reduce these interactions without substantially affecting the binding of the 
tagged protein to the Ni2+-NTA matrices. The addition of salt (up to 500 mM NaCl), glycerol 
(up to 20%), or low levels of ethanol (up to 20%) can also reduce non-specific hydrophobic 
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protein interactions with these matrices (Bornhorst and Falke, 2000). The washing and 
elution buffer conditions need to be optimized experimentally for individual proteins.  
 
There are several other options to improve the purification of His-tagged fusion proteins, 
besides the optimization methods mentioned above. These include additional purification 
steps using ion-exchange chromatography or size exclusion chromatography; the use of an 
engineered host strain that does not express certain proteins (however, this is not ideal since 
some of these proteins which may be co-purified with the target protein may be vital for the 
well-being of the host strain and the knock-out mutant could result in slow growth and low 
expression); and tag cleavage followed by reverse chromatography where the un-tagged 
target protein will be in the flow-through and the tag together with other co-purified 
contaminants are trapped in the column (Block et al., 2009).  
 
We attempted to express the target His-tagged fusion proteins in a mycobacterial host in 
order to produce these proteins using their native transcriptional and translational machinery. 
However, the expression vector p19Kpro could not express these proteins in significant 
amounts, probably because the promoter on this expression vector is not strong enough. 
Although this might have been solved by culturing a large volume of M. smegmatis for a 
large scale target fusion protein expression, we decided to rather use another mycobacterial 
expression vector (pDMN1) which has a very strong promoter Psmyc isolated from M. 
smegmatis. The results showed that even though this vector has a very strong promoter, only 
the combined esxG and esxH could be expressed in significant amounts using this vector. 
The other constructs appeared to be not functional, even though all constructs were verified 
to be correct and in frame using plasmid DNA sequencing. 
 
We hypothesize that overexpression of the proteins might be toxic since some of them are 
secreted T-cell antigens (e.g. esxG and esxH) which might exert cell lysis effects on host 
cells. The host M. smegmatis was possibly stressed and thus slowed down its growth or even 
shut down the target protein expression. We observed that, in an extreme case, the culture 
even died out (Figure 3.5, transformants of recombinant pDMN1-mycP3). The target protein 
could not be extracted even though the culture was initially able to grow. It is possible that 
the promoter sequence on the expression vector was mutated by the host so that the host 
could not be harmed by the incoming overexpressed toxic proteins (personal communication 
with M. Williams, unpublished results). Similar to what we observed in the expression of 
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esxG and esxH in E. coli, individually expressed esxG and esxH in M. smegmatis seemed to 
also be so toxic to the host, that the host shut down the expression; However when they were 
co-expressed, the toxicity seemed to be reduced and the host allowed them to be produced 
together in large amounts. 
 
The toxic effect of the overexpressed proteins to the host cells during expression could be 
reduced by making use of inducible expression. Since the mycobacterial expression vector 
pDMN1 is not an inducible expression vector, the toxic target fusion proteins were probably 
produced and began to harm the host from the moment when the transformant was cultured. 
An inducible expression vector is able to overcome such a problem, since the induction only 
begins after the culture is in its mid-log phase where the M. smegmatis host cells are 
relatively strong. This increases the production of target fusion proteins. There are several 
inducible expression systems that have been described so far (Sassetti et al., 2009). Future 
studies will be done with parallel expression in inducible expression vectors to ensure that 
toxic effects are identified and minimized. 
 
In spite of the low expression and poor purity of the mycosin-3 with/without transmembrane 
region, the His-tagged mycosin-3 was concentrated and used for protease assays immediately 
after the purification. It was assumed that no matter how low the quantity of mycosin-3 was, 
it should be able to perform its function when in solution with its potential substrate, provided 
that the enzyme was produced and folded correctly and was at its correct buffer conditions. 
Enzymes are made to catalyze biochemical reactions, so a small amount of mycosin-3 should 
still be able to cleave a significant amount of the substrate molecules if functional and under 
the correct conditions. 
 
After allowing for cleavage under the proposed optimal conditions, the samples were loaded 
onto 2-D PAGE gels. The results showed that the spots of interest (PE5, PPE4, combined 
esxG and esxH) in the experimental group did not deviate from the corresponding spots in the 
control group, irrespective of whether mycosin-3 with or without transmembrane region was 
used (Figure 3.7 – 3.9). There are a few possible reasons why the results showed no 
significant findings: (1) the buffer conditions that were used might not have favoured the 
activity of mycosin-3 with/without transmembrane region; (2) mycosin-3 and the potential 
substrates were not folded in its correct conformation or they were modified incorrectly and 
were thus no longer functional (E. coli is not an ideal expressing host for mycobacterial 
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proteins); (3) PE5, PPE4, the combined esxG and esxH are not the substrates of mycosin-3; 
(4) the 6x histidine tag on the target fusion proteins might interfere with the binding affinity 
between the mycosin-3 and the substrates; (5) mycosin-3 is not a real protease; (6) the 
contaminating proteins may exert an inhibitory effect on mycosin-3 (e.g. binding to mycosin-
3) so substrates could not access the binding pocket due to steric hindrance; or (7) the 
cleavage products were too small to be detected. 
 
Looking at all the 2-D gel results, a very large number of spots representing contaminating 
proteins could be observed, as well as breakdown products of large proteins and truncated 
products of the target proteins (section 6.4.2). In all the different gels, most spots appeared at 
the same location (i.e. same pI and molecular weight) and they are thus assumed to be 
common contaminants. By comparing the spots among different gels, the unique spots were 
assumed to be the target His-tagged fusion proteins, as well as their truncated products and 
modified products. In the gel where purified His-tagged PE5 fusion protein was loaded 
(Figure 6.34), there were a number of spots surrounding the predicted PE5 protein spot 
showing similar pI and molecular weight. These could not be found on other gels and they 
might be the truncated and modified products of PE5. ESAT-6 has been shown to have 
different protein species produced by M. tuberculosis including a form with an acetylated N-
terminus or a truncated C-terminus (Jungblut et al., 2008). PE5 might have similar different 
protein species as it is also a small secreted protein of the ESX gene cluster. Mycosin-3 
with/without transmembrane region is a much larger protein than PE5. Because of its low 
expression, it could not be identified as a clear spot on the 2-D gel stained with silver nitrate. 
Western blotting revealed a large amount of breakdown products (Figure 6.32b and Figure 
6.33b), as well as truncated and modified products with different pI from the original 
mycosin-3. Mycosin-3 without transmembrane region (Figure 6.32b) had more breakdown 
products than mycosin-3 with transmembrane region. The reason for this might be because 
the transmembrane region and the extracellular linker region have a protective effect on the 
functional domain of the protein. 
 
The gels on which purified combined esxG and esxH were loaded showed some spots 
(indicated with arrows in Figure 3.9) which could not be found in all other 2-D gels. EsxG 
and esxH were co-expressed and co-purified, and it is known from the literature that they 
tend to form a 1:1 complex. This complex was retained on the IEF gel because the conditions 
on the IEF strip is not denaturing. The complex migrated on the IEF gel according to the 
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combined pI of esxG and esxH. Theoretically, the esxG and esxH should have only 
dissociated from each other on the 2nd dimension SDS-PAGE. Therefore the black arrows 
indicating the two connecting spots are very likely to be the complex of esxG and esxH 
(Figure 3.9). The spots indicated with blue arrows probably represent the modified esxG or 
esxH since the molecular mass of this spot is very similar to esxG and esxH. It is interesting 
to note that different preparations of the purified combined esxG and esxH gave different 2-D 
gel profiles as indicated by the two spots with red arrows (Figure 3.9). These two spots are 
present in one 2-D gel [Figure 3.9 (a)] but absent in the other 2-D gel [Figure 3.9 (b)], 
indicating that they are not the target fusion proteins. They are likely the proteins whose 
production is cell culture stress dependent, i.e. stress-responsive proteins. Future studies will 
focus on confirming the identities of the spots on the 2-D PAGE gels by sending it for mass 
spectrometric sequencing. 
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Chapter 5 Conclusion 
 
We have successfully generated clones of mycosin-3 with/without the transmembrane region, 
PE5, PPE4, the combined PE5 and PPE4, esxG, esxH and the combined esxG and esxH in 
pET-28a E. coli expression vector as well as p19Kpro and pDMN1 mycobacterial expression 
vectors. All 22 clones were verified by colony PCR and plasmid DNA sequencing. We 
managed to express and purify these 9 different His-tagged fusion target proteins in E. coli 
and the combined esxG and esxH in M. smegmatis using two different purification methods; 
and we successfully conducted protease assays, IEF, 2-D SDS-PAGE and Western blotting. 
However, no substrate cleavage was observed in this project. The in vitro identification of 
potential substrates for mycosin-3 has not been successful thus far. This could be due to the 
following possible limitations: (1) impure enzyme and substrate(s); (2) inappropriate buffer 
conditions; (3) hypothesized substrates might not be the substrates of mycosin-3; and (4) 
incorrect folding or modification of the target fusion proteins. 
 
For future studies, we recommend that either the genes be cloned and expressed in 
mycobacteria using an appropriate inducible mycobacterial expression vector or the genes be 
codon-optimized for E. coli expression. Different affinity tags could be used instead of 6x 
Histidine since 6x His protein purification does not generate pure target fusion proteins. 
Alternatively, one or more chromatography steps can be performed after His-tag affinity 
chromatography. The substrates of mycosin-3 can be identified in vivo as well. Furthermore, 
the structure of mycosin-3, as well as the other four homologues will also be elucidated and 
analyzed; hence the enzyme binding pockets of mycosins will be modeled so that enzyme 
inhibitors can be designed for drug development. 
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Addendum  
 
A.1 Plasmid maps of expression vectors used in this project 
 
 
 
 
Figure A.1 Plasmid map of E. coli expression vector pET-28a 
 
 
 
 
Figure A.2 Plasmid map of M. smegmatis expression vector p19Kpro 
 
  
Figure A.3 Plasmid map of mycobacterial expression vector pDMN1
 
 
 
 
A.2 Detailed results of colony PCR confirmation of the clones
 
A.2.1 Results for pET-28a expression vector
 
Figure A.4 Image of colony PCR on pET
hydrophobic tail (lane 11 – 15, 1241 bp) transformants
 
Figure A.5 Image of colony PCR on pET
 
Figure A.6 Image of colony PCR on pET
 
Figure A.7 Image of colony PCR on pET
– 6, 1855 bp) and pET
 
 
 
 
 
 
 
-28a-mycosin-3 without hydrophobic tail (lane 1 
 
-28a-PE5 transformants (lane 1, 3, 4, 5 and 6, 311 bp)
 
-28a-PPE4 (1544 bp) transformant
 
-28a-esxH (lane 1, 293 bp) transformant, pET-28a
-28a-esxG (lane 7 – 10, 296 bp) transformants
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– 9, 1058 bp) or with 
 
 
 
-PE5&PPE4 (lane 4 
 
  
Figure A.8 Image of colony PCR on pET
 
A.2.2 Results for p19Kpro expression vector
 
Figure A.9 Image of colony PCR on p19Kpro
Figure A.10 Image of colony PCR on p19Kpro
Figure A.11 Image of 
Figure A.12. Image of colony PCR on p19Kpro
Figure A.13 Image of colony PCR on p19Kpro
Figure A.14 Image of colony PCR o
 
 
A.2.3 Results for pDMN1 expression vector
 
Figure A.15 Image of colony PCR on pDMN1
Figure A.16 Image of colony PCR on pDMN1
 
 
-28a-esxG&esxH (lane 2 – 5, 589 bp) transformants
 
 
-mycosin-3 (lane 1, 2 and 3) transformants
 
 
-esxG (lane 1, 2 and 5) transformants
 
 
 
colony PCR on p19Kpro-esxH (Lane 1 – 4) transformants
 
 
-PE5 (Lane 1, 2 and 3) transformants
 
-PPE4 (Lane 1, 2 and 3) transformants
 
 
n p19Kpro-PE5/PPE4 (Lane 1, 2, 3, 5 and 6) transformants
 
-mycP3 (Lane 1 – 5) transformants
 
-esxG (Lane 1, 2, 4 and 5) transformants
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Figure A.17 Image of colony PCR on pDMN1
transformants 
Figure A.18 Image of colony PCR on pDMN1
Figure A.19 Image of colony PCR on pDMN1
transformants 
 
 
 
 
A.3 Detailed results of expression and purification of 
 
A.3.1 Results for pET-28a expression vector (expression conditions are indicated)
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.20 Image of representative SDS
0.5 mM for 12 hours in E. coli (the area where the 
 
 
Figure A.21 Image of silver-stained SDS
conditions where purified His-tagged esxG fusion proteins were loaded
 
 
-esxH (Lane 1 – 7) and pDMN1-esxG/esxH (Lane 8 
 
-PE5 (Lane 1 and 3) transformants
 
-PPE4 (Lane 1 – 4) and pDMN1-PE5/PPE4 (Lane 5 and 6) 
His-tagged fusion proteins
 
-PAGE gel of test expression of pET-28a-esxG at 25°C with [IPTG] at 
His-tagged esxG should be found is indicated in the graph)
-PAGE gel of test expression of pET-28a-esxG under 9 different 
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– 10) 
 
 
 
 
 
 
 
  
 
Figure A.22 Image of silver-stained SDS
conditions where purified His-tagged esxH fusion proteins were loaded
 
 
 
Figure A.23 Image of silver-stained SDS
conditions where purified His-tagged esxG/esxH fusion proteins were loaded
 
 
 
Figure A.24 Image of silver-stained SDS
conditions where purified His-tagged PE5 fusion proteins were loaded
 
 
 
Figure A.25 Image of silver-stained SDS
conditions where purified His-tagged PPE4 fusion proteins were loaded
 
 
Figure A.26 Image of silver-stained SDS
conditions where purified His-tagged PE5/PPE4 fusion proteins
 
 
-PAGE gel of test expression of pET-28a-esxH under 9 different 
 
-PAGE gel of test expression of pET-28a-esxG/esxH under 9 different 
 
-PAGE gel of test expression of pET-28a-PE5 under 9 different 
 
-PAGE gel of test expression of pET-28a-PPE4 unde
 
-PAGE gel of test expression of pET-28a-PE5/PPE4 under 9 different 
 were loaded 
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r 9 different 
 
  
 
Figure A.27 Image of silver-stained SDS
tail under 9 different conditions where purified 
 
 
Figure A.28 Image of silver-stained SDS
under 9 different conditions where purified 
 
 
A.3.2 Results for pDMN1 M. smegmatis
 
Figure A.29 Image of silver-stained SDS
smegmatis at 37°C. The names of the proteins loaded in the lane are specified. Only combined esxG and esxH 
could be expressed and purified. 
 
 
-PAGE gel of test expression of pET-28a-mycP3
His-tagged mycP3-WT fusion proteins were loaded
-PAGE gel of test expression of pET-28a-mycP3
His-tagged mycP3-T fusion proteins were loaded
 expression vector 
-PAGE gel of expression of His-tagged fusion proteins in 
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-without hydrophobic 
 
 
-with hydrophobic tail 
 
 
M. 
  
 
Figure A.30 Image of colourimetric western blot of the duplicate polyarylamide gel shown in Figure 6.25. It 
confirms that only combined esxG and esxH was successfully expressed and purified from 
 
 
 
A.4 Detailed results of 2-D SDS
 
A.4.1 Protein quantification using Bradford assay
 
Figure A.31 The Standard curve of Bradford assay on a range of concentrations of Bovine Serum Albumin 
where the absorbance at 595 nm versus the concentration (mg/ml), the equation of this curve 
0.0518, the correlation factor is 0.9703
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-PAGE experiments and their western blots
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M. smegmatis. 
 
 
is y = 0.8333x + 
0.8
  
Table A.1 The amounts of freshly prepared 
Superflow column 
Name 
Mycosin-3 with 
transmembrane region 
Mycosin-3 without 
transmembrane region 
PE5 
PPE4 
Combined esxG and esxH 
 
A.4.2 The 2-D SDS-PAGE gels in the control group and their 
mycosin-3 antibodies 
 
Figure A.32 Silver-stain 2-D SDS-PAGE gel for the purified 
region fusion protein (a) and its western blot (b)
Figure A.33 Silver-stained 2-D SDS
region fusion protein (a) and its western blot (b)
 
 
His-tagged fusion proteins using Ni
Volume of 
original 
culture (Liter) 
Final 
Concentration 
(mg/ml) 
Final Volume 
(concentrate
(ml) 
3  13 0.6 
3 15 0.6 
2 11 0.7 
2 10 0.7 
1 15 0.6 
western blots using anti
(a)
His-tagged mycosin-3 without transmembrane 
 
(a)
-PAGE gel for the purified His-tagged mycosin-3 with transmembrane 
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-NTA 
d) 
Amount 
(mg) 
7.8 
9 
7.7 
7 
9 
-
(b) 
(b) 
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(a) (b) 
Figure A.34 Silver-stained 2-D SDS-PAGE gels for two different batches of purified His-tagged PE5 fusion 
protein (the most identifiable spot is the one pointed by an arrow) 
 
 
Figure A.35 Silver-stained 2-D SDS-PAGE gel for the purified His-tagged PPE4 fusion protein (the spot 
indicated by the square surrounded) 
 
 
(a) (b) 
Figure A.36 Silver-stained 2-D SDS-PAGE gel for two different batches of purified His-tagged combined esxG 
and esxH fusion proteins (the spots indicated by the arrows are probably esxG and esxH) 
